



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 7/06, 7/08, 16/42, A61K 39/395, G01N 33/563, 33/68	A2	(11) International Publication Number: WO 98/24808 (43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/US97/22348 (22) International Filing Date: 5 December 1997 (05.12.97) (30) Priority Data: 60/031,991 6 December 1996 (06.12.96) US (71) Applicant (for all designated States except US): THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH [US/US]; Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): PADLAN, Eduardo, A. [US/US]; 4006 Simms Drive, Kensington, MD 20895 (US). BIRGIT, A., Helm [DE/GB]; 3 Hopton House, 27, Collegiate Crescent, Sheffield S10 2BJ (GB). (74) Agent: EARP, David, J.; Klarquist, Sparkman, Campbell, Leigh & Winston, LLP, Suite 1600, One World Trade Center, 121 S.W. Salmon Street, Portland, OR 97204 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE (57) Abstract Peptides are disclosed that are capable of effective recognition of the human IgE Fcε receptor. The peptides partially comprises a fragment of human IgE. By addition of constraining amino acid residues at or near the polypeptides' N- and C-termini, these peptides may be forced to assume a loop configuration. These constrained peptides are useful as competitors of human IgE for the Fcε receptor, and may be used to block the development of type I hypersensitivity.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon		Republic of Korea	PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

**INHIBITION OF IgE-MEDIATED ALLERGIES
BY A HUMAN IgE-DERIVED OLIGOPEPTIDE**

This application claims priority from U.S. provisional application serial No. 60/031,991, filed December 6, 1996.

BACKGROUND OF THE INVENTION

Human IgE is believed to provide immunity to parasites. It
5 also mediates Type I hypersensitivity. Type I hypersensitivity is an allergic response leading to the manifestation of such symptoms as hay fever and asthma. Briefly, on encountering an antigen such as pollen, B-cells commence synthesis of antigen-specific IgE. The antigen-specific IgE then binds via its Fc region to cellular class
10 specific receptors and, thereafter, any further encounter with the antigen triggers degranulation of the cells releasing mediators. This is the cause of the acute inflammatory symptoms, hay fever and asthma, typical of Type I hypersensitivity.

Like all immunoglobulin, IgE comprises two heavy and two light
15 chains. The ϵ heavy chain consists of five domains, one variable domain VH, and four constant domains CH1 to CH4. The molecular weight of IgE is about 190,000 kd. The heavy chain is approximately 550 amino acid residues in length.

A 330 amino-acids long polypeptide, corresponding to amino acid
20 residues 218 to 547 of the ϵ heavy chain of IgE was shown to have an inhibitory effect on the release of mediators from human mast cells. The ϵ chain polypeptides apparently form dimers, i.e., two 330 amino acid long chains linked by disulfide bonds. See Nature 315: 577-78 (1985). The numbering of amino acid residues in the chain
25 corresponds to that proposed by Bennich for hIgE. See Bennich, PROGRESS IN IMMUNOLOGY II, Vol. I, at pages 49-58 (1974).

Strategies that block the initial sensitization of target cells with antigen specific IgE have been explored following the demonstration that human (h) myeloma IgE-derived Fc ϵ fragments
30 generated by papain cleavage, comprising h ϵ -chain residues 227-547, can competitively inhibit the binding of IgE to cells expressing high-affinity receptor (Fc ϵ R1). See Stanworth et al., Lancet 2: 17-

20 (1968); Ishizaka et al., *Immunochemistry* 7: 687-94 (1970). This observation initiated the quest for progressively smaller peptides as potential IgE antagonists.

More recent studies aimed at the identification of the receptor binding site(s) employed chimeric human/mouse IgE antibodies, ϵ/γ chimeras, site-specific mutagenesis, anti-IgE antibodies, or IgE derived peptides. See Robertson et al., *Mol. Immuno.* 25: 103-108 (1988); Stanworth, et al., *Lancet* 336: 1279-1283 (1990); Nio et al., *Peptide Chemistry* 2: 203-206 (1989); Weetal et al., *J. Immuno.* 145: 3849-3854 (1990); Nissim et al., *EMBO J.* 10: 101-107 (1991); Nissim et al., *Mol. Immuno.* 29: 1065-1072 (1992); Basu et al., *J. Biol. Chem.* 268: 13118-13127 (1993); Nissim et al., *J. Immuno.* 150: 1365-1374 (1993); and Presta et al., *J. Biol. Chem.* 269: 26368-26373 (1994). They indicate that the site(s) in IgE that interact(s) with Fc-receptors depend(s) on structures associated with residues located in the C ϵ 3 domain, although C ϵ 4 involvement has also been invoked. See especially Basu et al., *supra*; Stanworth, et al., *supra* (1988).

Extensive research to date has pointed to a number of apparently contradictory assignments regarding the mode of action and efficacy of such peptides. In part, this can be attributed to the assay employed for the assignation of biological activity. It has been claimed that short peptides containing between 5-76 amino acids, derived from a region spanning amino acids 265-547 of the Fc ϵ region will block the binding of human IgE to class-specific high- and/or low-affinity Fc receptors. See Hamburger *Science* 189: 389 (1975); Helm et al., *Nature* 331: 180 (1988); Helm et al., *Proc. Natl. Acad. Sci.* 86: 9465 (1989); Helm et al., *Progress in Allergy and Clinical Immunology* 2: 589 (1992); Weetal et al., *J. Immuno.* 145: 3849 (1990); Nissim et al., *supra* (1991); Nissim et al., *supra* (1992); Nissim et al., *supra* (1993); Basu et al., *supra* (1993); Stanworth et al., *supra* (1990); Robertson et al., *Mol. Immuno.* 25: 103 (1988); Presta et al., *supra*; Nio et al., *supra* (1989); Nio et al., *FEBS Lett.* 319: 225 (1993). Generally, Fc ϵ -derived peptides tested for the inhibition of binding of native antigen specific IgE have a lower affinity for the receptor than the native ligand. See Helm et al., *Progress in*

Allergy and Clinical Immunology 2: 589 (1992). They are therefore unlikely to act *in vivo* as effective competitive inhibitors.

SUMMARY OF THE INVENTION

5 An object of the present invention is to provide new oligopeptide(s) that are stable and highly active in anti-allergy treatment. Another object of the invention is to provide a method of preparing the oligopeptide by heterologous expression and isolation. Alternatively, the oligopeptide may be synthesized by known chemical synthetic methods.

10 Still another objective of the invention is to provide antibodies raised against the oligopeptide which can bind and thus inhibit IgE.

It is a further object of the invention to provide a pharmaceutical preparation in which the active ingredient is one of the oligopeptides. The preparation may also include a pharmaceutical carrier to permit clinical administration of the oligopeptide. It is yet another object of the invention to provide a pharmaceutical preparation in which the active ingredient is an antibody raised against one of the oligopeptides of the invention.

20 It is yet another object of the invention to provide a diagnostic method for estimating the level of IgE antibody in a sample. It is still a further object of the invention to provide a method for estimating the level of IgE antibody bound to Fcε receptors on FC_ε receptors expressing cells.

25 It is also an object of the present invention to facilitate targeting by drugs or diagnostic agents of cells that bear IgE high-affinity receptors.

In achieving these and other objects, there is provided, in accordance with one aspect of the invention, oligopeptides that
30 interact with the Fcε receptor, wherein the oligopeptide comprises:

P S P F D L F I R K S (Seq. I.D. No. 1)

In accordance with another aspect of the invention, there has been provided oligopeptides that interact with the Fcε receptor,

wherein said oligopeptide has been constrained to form a loop structure. For example, the oligopeptide can include C L S R at the N-terminal and P T I T S C C at the C-terminal (see Seq. I.D. No. 2).

5 In accordance with another aspect of the invention, there has been provided pharmaceutical preparations comprising an oligopeptide that has been constrained to form a loop structure.

In accordance with a further aspect of the invention, there has been provided DNA molecules encoding the oligopeptide and biological systems that express the DNA molecule. In a preferred embodiment,
10 the biological system is a prokaryotic or eukaryotic cell.

In accordance with still another aspect of the invention, there has been provided methods of preparing an oligopeptide competitor of IgE, comprising: culturing of the prokaryotic or eukaryotic cell and purifying the oligopeptide.

15 In accordance with yet another aspect of the invention above, there has been provided competitive binding assays for hIgE wherein the competitor is the oligopeptide competitor of IgE.

In accordance with still another aspect of the invention, there has been provided antibodies raised against the oligopeptide
20 competitor of IgE.

In accordance with yet a further aspect of the invention, there has been provided pharmaceutical preparations comprising antibodies raised against the oligopeptide competitor of IgE.

In accordance with still a further aspect of the invention,
25 there has been provided diagnostic methods for determining IgE levels in a sample of fluids comprising the steps of:

(a) contacting said sample with an antibody raised against an oligopeptide competitor to IgE; and

(b) precipitating IgE with said antibody.

30 In accordance with yet another aspect of the invention, there has been provided diagnostic methods for determining available Fcε receptors on the membrane of cells, comprising the steps:

(a) providing a sample of such cells;

(b) providing a labeled oligopeptide competitor to IgE; and

35 (c) determining the amount of label bound by said cells.

In accordance with still another aspect of the invention, there has been provided methods for targeting a cell which expresses FcεR1 receptor, comprising delivering an oligopeptide according to the present invention to an organism.

5 Kits for performing the above methods also are provided.

Proteins that interact with the FcεR1 receptor, wherein the proteins comprise the amino acid sequence P S P F D L F I R K S (Seq. I.D. No. 1), are provided. Also provided are proteins that compete with IgE for the FcεR1 receptor, wherein the proteins comprise C L S
10 R P S P F D L F I R K S P T I T S C C (Seq. I.D. No. 2). Proteins that compete with IgE for the FcεR1 receptor, wherein the protein consists essentially of (i) an amino acid sequence P S P F D L F I R K S, and (ii) constraining residues that flank the amino acid sequence of (i), wherein the constraining residues include cysteine
15 and are within 16 residues N-terminal and 4 residues C-terminal of the amino acid sequence of (i), also are provided.

These and other aspects of the invention will become apparent to the skilled person in view of the disclosure and data contained herein.

20 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Gene constructs, expression products, and mapping of receptor binding regions in human IgE. Recombinant ε-chain gene fragments were subcloned into the multiple cloning site (MCS) of the bacterial expression plasmids pGEX-3X and pGEX-KG and expressed in *E.*
25 *coli*. See Ho et al., *Gene (Amst.)*, 52: 2940-2948 (1989), Helm et al., *supra* (1988), and Helm et al., *Eur. J. Immuno.* 21: 1543-1548 (1991). The ε-chain expression plasmids pSV-V_{NP}he/re were employed for the construction of mutant and chimeric IgE molecules and expressed in the J558L myeloma cell line. See Helm et al., *supra*
30 (1991). Panels A and B summarize the ability of the truncated, chimeric, and mutant ε-chain variants to bind to FcεRIα expressed on RBL-2H3.1 and RBL-2/2/C cells and to FcεRII expressed on the 8866 lymphoblastoid cell line. See Wilson et al., *Eur. J. Immuno.* 23: 240-244 (1993) and Helm et al., *supra* (1991). Initial screening for

biological activity was determined by assessing the capacity of GST·e-chain fusion proteins to inhibit the binding of ¹²⁵I-labeled hIgE (1 nM) to the receptors. For a description of GST·e-chain fusion proteins see Helm et al., *J. Biol. Chem.* 271: 7494-7500

(1996). The degree of inhibition effected by nonbinding ligands was identical, within limits of experimental error, to that observed with GST, which was included as a negative control (see Figure 2).

Purification of truncated recombinant GST·e-chain fusion proteins and mutant and chimeric IgE molecules was carried out as described in

Examples. Ligands were labeled with ¹²⁵I for direct binding studies (see Table I). Nonbinding ligands showed no binding above background levels even at concentrations above 10⁻⁵ M. Panels C and D show GST·e-chain fusion proteins that were immuno precipitated with a rabbit anti-GST serum, followed by SDS-PAGE (12%) separation under nonreducing conditions and immunoblotting with a horseradish peroxidase-labeled rabbit anti-human IgE serum. Panel C, lanes 1-6, GST·e-(226-547), GST·e-(226-361), GST·e-(226-357), GST·e-(226-354), GST·e-(226-352), GST·e-(226-340), Panel D, lanes 1-6, GST·e-(326-547), GST·e-(340-547), GST·e-(343-547), GST·e-(345-547), GST·e-(350-547), GST·e-(226-440)-Cγ3. +, receptor binding; -, loss of receptor binding; n.d., not determined.

Figure 2. Percentage of inhibition of ¹²⁵I-hIgE binding to RBL-2/2/C cells by native and recombinant hIgE-derived e-chain fragments. To measure the inhibition (IC₅₀) of ¹²⁵I-hIgE to RBL-2/2/C cells by native IgE and recombinant e-chain fragments, cells were preincubated at 22°C for 1 h with increasing concentrations (10⁻¹² - 10⁻⁵ M) of each of the unlabeled GST fusion peptides in 125 μl of binding buffer or, as a negative control, GST or binding buffer. ¹²⁵I-hIgE was then added (1 nM). After 45 min. the cells were washed twice with 0.5 ml of binding buffer and lysed in the same volume of lysis buffer, and aliquots were removed for γ-counting. The IC₅₀ values for GST·e-(226-547) and GST·e-(226-357) (data not known) were identical to those observed for hIgE (▲) and GST·e-(226-354) (Δ). In GST·e-(226-340) and GST·e-(335-547), the sequence common to all fragments that can engage FcεRI has been deleted by either the N- or C-terminal truncation. GST·e-(226-340) (○) and GST·e-(335-547) (■)

show inhibition levels similar to that obtained with GST (□) and all other fragments classified as nonbinding ligands in Figure 1. ♦, GST·e-(340-547); ○, GST·e-(440-547). Data shown represent the means of at least three separate experiments carried out in duplicate.

5 Figure 3. Drawing of the α -carbon trace of a model structure for hIgE with various fragments and domains indicated. The light chains are drawn with thin lines and the heavy chains with thick lines, one thicker than the other. The interchain Cys at position 328 is labeled. The 11-amino acid segment 343-353, which is common
10 to all IgE-derived peptides that bind to Fc ϵ RI, is drawn with larger circles and wide, empty bonds in heavy chains.

 Figure 4. pH profile for the binding of native IgE and recombinant IgE-derived peptides to RBL-2/2/C cells. h α -chain-transfected RBL-2/2/C clones were distributed into 48-well plates at
15 10^5 cells/well and incubated with 10^{-6} M dexamethasone for 24 h at 37°C. Prior to the assay cells were washed twice with 0.5 ml of saline containing 0.4% BSA and preincubated with 125 μ l of 50 mM phosphate-buffered saline containing 0.4% BSA (pH range 5.9-8.1) for 10 min at 37°C before adding 50 μ l of 2 μ g of 125 I-labeled IgE (□),
20 0.7 μ g of GST·e-(340-547) (♦), and GST·e-(226-354) (□). Cells were incubated for 30 min, after which unbound ligand was removed by washing with binding buffer before measurement of cell-bound label. Results were corrected for nonspecific binding. (Data shown represent the means of two determinations carried out in duplicate.)

25 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

1. Definitions

Core Sequence: In the present invention, "core sequence" refers to an 11 amino acid sequence which has been identified as the minimal region of IgE required for interaction with Fc ϵ receptors.

30 Constrained: In the present invention, a "constrained" molecule is a short molecule, typically an oligopeptide, comprising residues that affect the shape of the oligopeptide. The constraint is introduced by residues near or at the ends of the oligopeptide. Such residues link to each other, generally by forming disulfide
35 bonds which constrain the shape of the molecule into a loop-like

structure. Often the residues involved in creating a constraint are cysteines.

Loop Configuration: Model studies have suggested that the IgE region that interacts with the Fcε receptor forms a loop-like structure. See Helm et al., *supra* (1991) and Padlan & Helm, *Biochem. Soc. Transactions* 21: 963-967 (1993). According to this description, "loop" refers to a native-like configuration achieved by an oligopeptide comprising the core sequence and further constrained as above, so that the ends of the oligopeptide are in close proximity.

Residue: The IgE competitor molecule of the invention includes oligopeptides. Its constituents or chemical entities (its subunits) of the competitor molecule typically are amino acids. According to some embodiments, however, other entities can be introduced into what is still called an "oligopeptide" in this description. Those may be modified amino acids or other groups possessing desired features. For example, any chemical residue that has a carboxyl group may allow formation of a covalent bond to another molecule. Also, some non amino acid residues, such as methylene, carboxymethylene, and carboxidiimide, may allow disulfide-like bonds within the oligopeptide.

Oligopeptide: The oligopeptide of the present invention is defined as a molecule of about 50 residues or smaller. Part of the sequence of this molecule is the core sequence defined above. The oligopeptide is constrained as defined above, by additional residues.

2. Overview

It has been discovered for the first time that a particular peptide, Pro343-Ser353, is common to all polypeptides that can bind the high- and low-affinity IgE receptors. An understanding of the native structure of the binding domain by three-dimensional modelling of the binding site for IgE was developed. These studies have provided information regarding the structural motif that is required for an oligopeptide to be effective in mimicking IgE in its interaction with class-specific Fc receptors. Based on those findings, model constrained oligopeptides were proposed and tested for binding Fcε receptors. The testing of those oligopeptides

includes a determination of the rate of association and disassociation to receptors, and their ability to compete with IgE. Methods for testing such activity have been described. See Wilson et al., *supra*; Wilson et al., *J. Clin. Immunoassay* 16: 91-95 (1993); and
5 Helm et al., *supra* (1991).

A useful oligopeptide would be relatively small, so that it will be easy to synthesize and deliver. An additional advantage of a small but effective oligopeptide is that its therapeutic/
prophylactic use is less likely to trigger an adverse, i.e.
10 anaphylactic, immune response.

However, a small peptide might not assume the structure of the segment as found in the intact molecule. The three-dimensional structure of a polypeptide is determined by its amino-acid sequence and its environment and conformation. Fragments which are too small
15 will not have the environment found in the intact molecule. Such fragments, freed from structural constraints, will assume many other conformations. See Wright et al., *Biochem.* 27: 7167 (1988). The probability that a peptide will assume the proper conformation, i.e. that which is found in the intact molecule is very small. Improper
20 configuration will likely be manifested in a greatly reduced binding affinity. Low binding affinities will require the administration of large doses of peptide for effectiveness. This difficulty can be obviated by imposing structural constraints on the peptide segment.

According to one embodiment of the invention, a molecule was
25 designed that comprises the core sequence that is required for the binding of IgE to its receptors. This embodiment is further constrained so that its structure mimics that which has been predicted for the segment as found in the intact IgE molecule. The sequence is:

30 C L S R P S P F D L F I R K S P T I T S C C (Seq. I.D. No. 2).

The oligopeptide of the embodiment thus comprises an IgE derived sequence extending past the core sequence: L S R P S P F D L F I R K
S P T I T which is the Leu340-Thr357 fragment from the human IgE sequence, and additional amino acids at the N- and C- termini of the
35 peptide. In those sequences, the Pro343-Ser353 core fragment P S P F D L F I R K S (Seq. I.D. No. 1) is underlined.

In the one embodiment, the Ser after Thr357 was added to improve the solubility of the peptide; other amino acids, such as Thr, Asp, Asn, Glu, Gln, Tyr, or His could have been used also. The starting and penultimate Cys were added to provide the intramolecular
5 disulfide linkage. Thus the oligopeptide forms a loop and is active only when incubated under conditions that promote disulfide bond formation. The C-terminal cysteine was added for possible linkage to a carrier molecule or pharmacologically active agent; such linkage may not be needed or desired, depending on the chosen application or
10 mode of administration of the oligopeptide. Other amino acids could be used to link to a second molecule and may be introduced at either the N- or the C-terminus.

In other embodiments, longer or shorter oligopeptides which contain the residues required for binding to receptor, likewise
15 constrained by disulfide bonds or the like, also will be effective. Examples of shorter, constrained oligopeptides are:

C S R P S P F D L F I R K S P T I T C C (Seq. I.D. No. 3)

C R P S P F D L F I R K S P T S C C (Seq. I.D. No. 4)

C P S P F D L F I R K S P T C C (Seq. I.D. No. 5)

20 where the underlined sequence is the core sequence required for binding the receptor.

According to other embodiments, the terminal Cys may or may not be needed or desired, depending on whether the oligopeptide is to be linked to an additional effector molecule or not. In yet other
25 embodiments, other amino acids may be substituted for residues outside the recognition motif, or within the recognition motif, to improve the solubility or other physical chemical property of the oligopeptide or to enhance its biological activity. Very small insertions or deletions (usually no more than a few amino acids) are
30 also possible. Shorter and longer polypeptides may allow folding such that the core sequence is in a configuration like the native configuration. However, practically speaking, peptides outside certain lengths are less likely to achieve the desired configuration. In a preferred embodiment, the oligopeptide is fewer than 50 and more
35 preferably 13-27 residues in length. Furthermore, other means of

constraining the recognition peptide to its loop-like conformation as found in the intact molecule may be used also.

Other chemical structures could be utilized to constrain the oligopeptide. For example, linkages involving methylene, carboxymethylene, carboxidiimide fragments, etc. have been utilized. See for example Dutta et al, *J. Med. Chem.* 33: 2552-2560, 2560-2568 (1990); Sham et al, *J. Med. Chem.* 31: 284-295 (1988); Thaisrivongs et al., *J. Med. Chem.* 31: 1369-1376 (1988), and 34: 1276-1282 (1991); Weber et al., *J. Med. Chem.* 34: 2692-2701 (1991). It may also be desirable to replace groups inside or outside the receptor motif with peptidomimetic or other moieties for the purpose of improving the binding properties of the molecule, or its physical chemical properties. Such changes would result in an oligopeptide that adheres to the principles of the present invention and thus are within the scope of the invention.

Exemplary uses for an oligopeptide that mimics the epsilon (ε) heavy-chain region of IgE include the capacity (a) to inhibit the binding to class-specific receptors and thus prevent the release of cellular mediators from cells expressing the receptors, (b) to stimulate the formation of non-anaphylactic anti-IgE antibodies which can bind to membrane IgE and inhibit B-cell synthesis of IgE by down regulation of its synthesis, (c) when linked to a pharmacologically active agent, to selectively destroy cells expressing Fcε receptor-bearing cells, and (d) to inhibit IgE/CD23 facilitated antigen presentation. The oligopeptide thus can be used prophylactically or as a treatment. In addition, the constrained oligopeptide can be used *in vitro* to determine receptor availability and receptor occupancy by IgE. In such tests, the polypeptide, or IgE, can be labeled to enhance detection.

An antibody raised against such an oligopeptide also has utility due to its interception of IgE in the plasma, away from the Fcε receptor. Antibodies raised against the oligopeptide, as opposed to an anti-Ab antibody, are likely to display less cross-reactivity. Furthermore, antibodies raised against antibodies can sometimes mimic the original antigen and worsen the hypersensitivity state. Antibodies raised against the oligopeptide of the invention reduce

the risk of increasing hypersensitivity, since they do not recognize receptor bound IgE. The antibody can inhibit IgE/CD23 facilitated antigen presentation, and, when linked to a pharmacologically active agent, can selectively destroy cells expressing membrane IgE.

5 According to one aspect of the invention, antiserum is raised against any of the oligopeptides of the invention. According to one embodiment, polyclonal or monoclonal antibodies, including humanized antibodies are prepared. Such antibodies are used as a prophylactic or therapeutic treatment, by virtue of their binding to IgE in the
10 plasma but not to IgE bound to cellular receptor.

 According to one embodiment of the invention, sera was raised against the oligopeptide: C L S R P S P F D L F I R K S P T I T S C C (Seq. I.D. No. 2). It was shown that only oligopeptide pre-incubated under conditions that allow S-S bridges to form produced sera which
15 can bind IgE in solution. Furthermore, the sera did not produce hypersensitivity. The antibody appears not to bind IgE when IgE is bound to the Fcε receptor.

 It is well known that IgE plays a role in the response of an organism to parasites. See Hagan et al., *Nature* 349: 243-45 (1991).
20 Furthermore, high levels of IgE have been correlated with AIDS. See Wright et al., *J. Allergy Clin. Immun.* Feb: 445-52 (1990), and Lin et al., *Ann. Allergy* 61: 269-72 (1988). Thus, determination of either the IgE titer in a sample, or the level of expression or availability of Fcε receptor on cell surface would be desirable. Hence, labeled
25 antibody raised against the constrained oligopeptide of the invention and the constrained oligopeptide itself, have useful application in diagnostic assays. According to one embodiment of the invention, the oligopeptide can be used to determine the level of expression of IgE receptors and/or the levels of receptor available to bind IgE.
30 According to another embodiment, the titer of IgE in a sample can be estimated by employing antibody specific for the constrained oligopolypeptide.

3. *A DNA Molecule Encoding the Oligopeptide of the Invention*

 According to one object of the invention, an oligopeptide is
35 provided which mimics IgE in its ability to bind Fcε receptor.

According to one embodiment, the oligopeptide comprises Cys residues near the termini which constrain and thus shape a polypeptide into the desired configuration by providing intramolecular S-S bonding, i.e. forming a loop. According to a preferred embodiment, the oligopeptide further comprises additional amino acids which either do not affect its activity, or impart benefits, such as improved solubility, stability or an optimum size. According to a further preferred embodiment, a C-terminal or N-terminal amino acid is added to allow for covalent linkage of the oligopeptide to another molecule. The oligopeptide thus designed could be chemically synthesized. Chemical synthesis of peptides is well known to an artisan skilled in the field. It could allow the introduction of modified amino acids, or linkage of groups other than an amino acids.

However, in a preferred embodiment, the oligopeptide according to any of the embodiments above is a translation product of a gene encoding the oligopeptide. The gene, and the variations of the gene according to the embodiments above, can be produced by many methods. For example, a set of complementary oligonucleotides could be designed. If need be, "batch ligation" of sets of such oligonucleotides could be employed. That is, if the coding region is too long to be covered by one set of complementary oligonucleotides, ligation of sets of complementary oligonucleotides can be employed. In either case, the oligonucleotides would be so designed as to allow subsequent subcloning into an expression vector.

Alternatively, one can take advantage of the fact that this segment has been cloned and expressed as a GST fusion peptide which does not form a loop. See Helm et al., *supra* (1996). PCR or NASBA could be applied, employing mutagenic primers, so a subsection of the DNA containing changes would be amplified and subcloned. Yet another alternative would be that a section of interest from the gene would be subcloned (by amplification as above, or by the "cut and paste" of molecular cloning) into a vector that can produce single stranded DNA. This would facilitate employment of mutagenic primers, employing well known techniques and commercially available kits. Finally, combinations of the above methods, to allow further

variation of a gene sequence encoding the desired oligopeptide, could be employed by one skilled in the art. The changes envisioned, at the protein level, could result in substitution, insertion or deletion of a few amino acids.

5 Substitutional variants typically contain the exchange of one amino acid for another at one or more sites within the protein, and are designed to modulate one or more properties of the protein such as stability against proteolytic cleavage. Substitutions could be conservative, that is, one amino acid is replaced with one of similar
10 shape and charge. Conservative substitutions are well known in the art and include, for example, the changes of: alanine to valine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; histidine to asparagine or glutamine; isoleucine to
15 leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine, or glutamate; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine.
20 Changes involving less conservative substitutions also can be made according to the invention.

 Insertional variants may alter the sequence of the oligopeptide competitor of IgE or may be used to create fusion proteins such as those used to allow rapid purification of the protein (see below).
25 Insertional variants may also produce hybrid proteins containing sequences from other proteins. Other insertional variants can include those in which additional amino acids are introduced within the coding sequence of the protein. These typically are smaller insertions than the fusion proteins described above and are
30 introduced, for example, to disrupt a protease cleavage site or modify chemical or biological properties of the oligopeptide. Deletional variants would remove one or a few amino acids from the oligopeptide.

 In one embodiment, peptides produced from translation of a gene
35 are subjected to further chemical manipulation, so modification of the peptide is achieved.

The methods employed to introduce such changes are well known in the art. Some often-used manuals describing relevant experimental protocols and techniques are Ausubel, ed., in CURRENT PROTOC. MOLEC. BIOL., vols. 1-3, Wiley Interscience Publ., and also Murray ed.,
5 METH IN MOLEC. BIOL., especially vol. 7, GENE TRANSFER AND EXPRESSION PROTOC., (1991); vol. 9, PROTOC. IN HUMAN MOL. GENE., Mathew ed., (1991); and vol. 15, PCR PROTOC., White ed., (1993), Humana Press, Totowa, NJ. See also U.S. Patent No 5,409,818.

4. *Expression and Purification of the oligopeptide*

10 According to another embodiment of the invention, a DNA encoding an oligopeptide sequence as described above is used to recombinantly produce protein. For this purpose, the DNA is operably linked into a vector to transcriptional/translational features, according to methods well understood by those skilled in the art.
15 Typically, the DNA sequence encoding a protein/peptide product will be inserted downstream from a promoter. Downstream of the coding sequence there will be a terminator sequence. In general, host-cell specific sequences improving the production yield will be used and appropriate control sequences will be added to the expression vector,
20 such as ribosome binding sites, and, in eukaryotes, enhancer sequences, and polyadenylation sequences. The construct can be expressed in a variety of systems; for example in mammalian cells, baculoviruses, bacteria and yeast, as discussed below.

Each such host system would have advantages and disadvantages to be considered in any given circumstance. For example, bacterial
25 expression would be easy, inexpensive and efficient. Proper folding or modifications, or potentially of more immediate interest in the present invention, disulfide bond formation in vivo, would necessitate use of eukaryotic cell systems. Those choices are
30 rationally made by the skilled artisan in light of the specific gene fragment to be expressed, and its ultimate use. Vectors for expression in each such host are commercially available.

Thus, the present invention also relates to a host cell stably transformed with any of the above described DNAs of the invention,
35 wherein the transforming DNA is capable of being expressed. Such

host cell can be a prokaryote or eukaryote. Preferred host cells include bacterial, insect, mammalian and yeast cells, or whole organisms such as insects or plants. Methods for the transformation of such host cells with the DNA of the present invention and methods of culturing the same would be well-known to the skilled artisan.

In a preferred embodiment, oligopeptides according to the invention are cloned and expressed in *Escherichia coli* (*E. coli*). Larger ϵ chain fragments are known to express in *E. coli*. See *Eur. J. Immuno.* 15: 966-69 (1985); and *Proc. Nat'l Acad. Sci. USA* 81: 2955-59 (1984). Furthermore, small peptides have been expressed as GST fusion peptides which could be cleaved from GST by thrombin. See Helm et al., *supra* (1996).

5. Antibody Production and Related Methods

Antibodies against the oligopeptide of the invention can be obtained using the product of an expression vector as an antigen. The preparation of polyclonal antibodies is well-known to those of skill in the art. See, for example, Green, "Production of Polyclonal Antisera," in *IMMUNOCHEMICAL PROTOCOLS*, Manson, ed., pages 1-5, Humana Press (1992). In a preferred embodiment, rabbit polyclonal sera was prepared against one of the oligopeptides of the invention.

Alternatively, an anti-oligopeptide antibody of the present invention may be derived from a rodent monoclonal antibody (MAb). Rodent monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art. See, for example, Kohler and Milstein, *Nature* 256: 495 (1975), and Coligan (eds.), *CURRENT PROTOCOLS IN IMMUNOLOGY*, VOL. 1, pages 2.5.1-2.6.7 (John Wiley & Sons 1991). Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising an antigen, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.

MAbs can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography. See, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3. Also, see Baines et al., "Purification of Immunoglobulin G (IgG)," in *METHODS IN MOLECULAR BIOLOGY, VOL. 10*, pages 79-104 (The Humana Press, Inc. 1992).

An anti-polypeptide antibody of the present invention may also be derived from a primate. For example, general techniques for raising therapeutically useful antibodies in baboons may be found, for example, in Goldenberg, international patent publication No. WO 91/11465 (1991), and in Losman et al., *Int. J. Cancer* 46: 310 (1990).

Alternatively, a therapeutically useful anti-oligopeptide antibody of the present invention may be derived from a "humanized" monoclonal antibody. Humanized monoclonal antibodies are produced by transferring mouse complementarity determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, and then, substituting human residues in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by the publication of Orlandi et al., *Proc. Nat'l Acad. Sci. USA* 86: 3833 (1989), which is incorporated by reference in its entirety. Techniques for producing humanized MAbs are described, for example, by Jones et al., *Nature* 321: 522 (1986), Riechmann et al., *Nature* 332: 323 (1988), Verhoeyen et al., *Science* 239: 1534 (1988), Carter et al., *Proc. Nat'l Acad. Sci. USA* 89: 4285 (1992), Sandhu, *Crit. Rev. Biotech.* 12: 437 (1992), and Singer et al., *J. Immuno.* 150: 2844 (1993).

As an alternative, an antibody of the present invention may be derived from human antibody fragments isolated from a combinatorial immunoglobulin library. See, for example, Barbas et al., *METHODS: A Companion to Methods in Enzymology* 2: 119 (1991), and Winter et al.,

Ann. Rev. Immuno. 12: 433 (1994), which are incorporated by reference. Cloning and expression vectors that are useful for producing a human immunoglobulin phage library can be obtained, for example, from STRATAGENE Cloning Systems (La Jolla, CA).

5 In addition, antibody of the present invention may be derived from a human monoclonal antibody. Such antibodies are obtained from transgenic mice that have been "engineered" to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain locus are introduced into
10 strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human
15 antibodies from transgenic mice are described by Green et al., *Nature Genet.* 7: 13 (1994), Lonberg et al., *Nature* 368: 856 (1994), and Taylor et al., *Int. Immuno.* 6: 579 (1994).

6. *The oligopeptide as a Targeting Molecule*

20 The oligopeptide of the invention, when covalently bound or simply associated to another agent, could, by virtue of its affinity for the FcεR1, deliver such other agent to a cell that expresses the receptor. In the examples given herein, a Cys at the C-terminus of the oligopeptide is designated to facilitate just such association. Such agent could include for example a drug, a radiolabeled molecule,
25 or any agent that could be diagnostic, or therapeutic, or used as a research tool. For example, liposomes are one method of delivery of agents to cells in an organism. They are sometimes targeted to the cell type or tissue of interest by the addition to the liposome preparation of a ligand, usually a polypeptide, for which a
30 corresponding cellular receptor has been identified. Examples of cell receptors previously targeted include the folate receptor, which has recently been identified as a prominent tumor marker, especially in ovarian carcinomas. KB cells are known to vastly overexpress the folate receptor. See Campbell et al., *Cancer Res.* 51: 6125-32
35 (1991). Yet other targeting ligands have been examined for liposome

targeting including transferrin, protein A, ApoE, P-glycoprotein, α_2 -
macroglobin, insulin, asialofetuin, asialoorosomucoid, monoclonal
antibodies with a variety of tissue specificities, biotin, galactose-
or lactose- containing haptens (monovalent and tri-antennary),
5 mannose, dinitrophenol, and vitamin B12. The ligands are covalently
conjugated to a lipid anchor in either pre-formed liposomes or are
incorporated during liposome preparation. See Lee & Low, *J. Biol.*
Chem. 269: 3198-04 (1994); *Biochim. Biophys. Acta* 1233: 134-44
(1995).

10 In one embodiment of the invention, the association of the
oligopeptide of the invention with a delivery agent as described
above includes association with additional targeting agents. For
example, in order to gain access to the cytoplasm, the DNA molecule
must overcome the plasma membrane barrier. In nature, viral fusion
15 peptides facilitate the delivery of viral DNA into the cytoplasm by
promoting viral membrane fusion with the plasma membrane. For recent
reviews on this subject, see Stegmann et al., *Ann. Rev. Biophys.*
Chem. 18: 187-221 (1989). For the influenza virus, the hemagglutinin
(trimer) HA peptide N-terminal segment (a hydrophobic helical
20 sequence) is exposed due to a conformational change induced by acidic
pH in the endosome (pH 5-6), inserts into the target membrane, and
mediates the fusion between the virus and the target endosomal
membrane. See Weber et al., *J. Biol. Chem.* 269: 18353-58 (1994).
Recently, several amphipathic helix-forming oligopeptides have been
25 designed to imitate the behavior of the viral fusion peptide. See,
for example, Haensler & Szoka, *Biocon. Chem.* 4: 372-79 (1993).

Nuclear localization signal peptides, when attached covalently
to a macromolecule such as a protein, have been shown to facilitate
their translocation into the nucleus. See Goldfarb et al., *Nature*
30 322: 641-44 (1986); Shreiber et al., *Med. Sci.* 8: 134-39 (1992). By
the combination of cellular targeting by the oligopeptide of the
invention and nucleus targeting, yet other agents could be delivered
in the nucleus of specific cells, for example DNA molecules.

7. *Delivery of the Therapeutic Agents to a Patient*

Delivery of any of the above therapeutic agents or antibodies requires administration to the patient of therapeutically effective doses. "Administering" the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan.

The pharmaceutical compositions are preferably prepared and administered in dose units. Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the patient, different daily doses are necessary. Under certain circumstances, however, higher or lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and also by multiple administration of subdivided doses at specific intervals.

The pharmaceutical compositions according to the invention are preferably administered intravenously. However, other routes of administration can be readily ascertained. Thus, the pharmaceutical compositions can be administered topically, intravenously, orally or parenterally or as implants, even rectal use as appropriate. Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of present methods for drug delivery, see Langer, *Science*, 249: 1527-1533 (1990), which is incorporated herein by reference.

The pharmaceutical compositions according to the invention may be administered locally or systemically. By "therapeutically

effective dose" is meant the quantity of a compound according to the invention necessary to prevent, to cure or at least partially arrest the symptoms of the disease and its complications. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the patient. Typically, dosages effective in vitro may provide useful guidance in the amounts useful for in situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various considerations are described, e.g., in Gilman et al. (eds.) (1990) GOODMAN AND GILMAN'S: THE PHARMACOLOGICAL BASES OF THERAPEUTICS, 8th ed., Pergamon Press; and REMINGTON'S PHARMACEUTICAL SCIENCES, 17th ed. (1990), Mack Publishing Co., Easton, Pa.

The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to limit the present invention.

Example 1. Gene constructs and site specific mutagenesis

The numbering scheme for heavy-chain amino acid residues used in previous publications has been maintained. See Helm et al., *supra* (1988); Vercelli et al., *Nature* 338: 649-652 (1989); Helm et al., *supra* (1989); Helm et al., *supra* (1991). Herein, "h" stands for human and "r" stands for recombinant. The polymerase chain reaction (PCR) was used to amplify heavy-chain fragments comprising the entire Fc region (226-547), the C γ 3 from mouse IgG2a, the C ϵ 2 domain (226-329), and the C ϵ 4 domain (440-547). N-terminal deletions of the Fc region were prepared starting at amino acid residue positions 326, 330, 340, 342, 343, 344, 345, 350, and 355 and terminating at residue 547. C-terminal deletions were prepared starting at amino acid residue 226, and terminating at residues 361, 357, 354, 353, 352, 345 and 340. The DNA products were purified by agarose gel electrophoresis, digested with appropriate restriction enzymes, and subcloned into the bacterial expression plasmids pGEX-3X and pGEX-KG, which direct the synthesis of foreign polypeptides in *E. coli* as fusions with the 26 kDa glutathione-S-transferase (GST). See Guan et al., *Anal. Biochem.*

192: 262-267 (1991). Cloning the recombinant ϵ -chain fragments in frame to the 3' end of the GST gene facilitates the production of large amounts of fusion protein (~500 mg/L). In addition to a versatile multiple cloning site, the vectors have been engineered so that the GST carrier can be cleaved off by digestion with coagulation factor Xa or thrombin. The initial screening for receptor blocking activity was carried out with partially purified GST- ϵ -chain fusion polypeptides. Following affinity purification on rabbit anti-GST affinity columns, and GST removal with thrombin, ϵ -chains showed identical receptor blocking capacities when compared to GST- ϵ -chain fusion polypeptides. Therefore this step was eliminated and all assays described in this study were carried out with affinity purified GST- ϵ -chain fusion polypeptides. Short GST fusion peptides comprising ϵ -chain residues 338-359 and 340-357 were also generated. Site-specific mutagenesis was performed by overlap extension PCR (Ho *et al.*, *supra*). Bacterial strains used as host for transformation were JM109 or MC1061.

For the construction of the chimeric h/r IgE molecule we employed the ϵ -chain expression plasmids PSV-VNp ϵ /r ϵ Helm *et al.*, *supra* (1991). A construct where the sequence known to be essential for hFc ϵ R1 interaction has been replaced by the homologous rat sequence encoding residues 341-356 was also generated by overlap extension PCR. See Ho *et al.*, *supra*. The template for PCR was a 3.4 kb IgE C ϵ _{1,4} genomic DNA cassette cloned into the BamHI site in pUC19 (pHe). A 719 bp fragment coding essentially for C ϵ 2-3 was generated by PCR.

This involved PCR reactions employing four primers, two external primers 5'- CGTGAAGATCTTACAGTCGTC -3' (Seq. I.D. No. 6) and 5'- CCTGCCCCATGGCTCACCG -3' (Seq. I.D. No. 7), and two internal primers 5'- CCTCGACCTGTATGAAAATGGG ACTCCCAAACCTTACCTGTCTGGTGGTGACCTG -3' (Seq. I.D. No. 8) and 5'- CCATTTTCATACAGGTCGAGGGGACTGGGTGGGATTAGGTAGGCG-CTCACCCCTCT -3' (Seq. I.D. No. 9). The external primers had Bgl II and Nco I restriction enzyme sites build in the sequence, respectively. For each PCR reaction, mixtures contained 200 ng of template, 2 μ g of each primer, 1 mM dNTPs, 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl₂ in 100 μ l,

and following a hot start 1U Taq polymerase was added. An initial denaturation cycle at 96°C/6 mins, 64°C/2 mins, 72°C/1 min and 30 seconds was followed by 30 cycles 94°C/1 min 30 seconds, 64°C/1 min 30 seconds, 72°C/1 min 30 seconds. The resultant 719 base pairs
5 fragment was cloned into pHe using the *Bgl* II and *Nco* I sites to give a chimeric Cε1-4 cassette which was subcloned, using the *Bam*HI sites, into the mammalian expression vector pSV VNP (Helm et al., *supra* (1991)). The orientation of this cassette was checked by PCR.

10 The identity of all gene constructs was confirmed by sequencing the DNA of both strands.

Example 2. Gene expression and purification of peptides

E. coli strains transformed with the expression plasmids were grown overnight at 37°C and the overnight culture was diluted 100 fold into LB broth containing 100µg/ml ampicillin and grown to an
15 absorbance of 0.4 at 600 nm at 37°C. The inducer IPTG (Sigma) was added to a final concentration of 0.1 mM and the cultures were grown under constant shaking at 37°C for 4h. Bacterial cells were harvested by centrifugation at 5,000g for 15 min and the pellets were frozen at -70°C until purification of the recombinant proteins.
20 Freezing and subsequent thawing of the bacterial pellets were essential to obtain effective solubilization of the recombinant proteins which are expressed as insoluble inclusion bodies.

The chimeric pSV VNP construct was linearized using *Pvu* I and electroporated into the J558L plasmacytoma cell line. See Helm et
25 al., *supra* (1991). J558L cells were cultured in DMEM (10% FCS, Pen/Strep, Gentamicin) and selection medium (DMEM 10%FCS, Pen/Strep, Gentamicin, Mycophenolic acid, Xanthine and Hypoxanthine) was added 48 hours after electroporation. See Helm, et al., *supra* (1991). High secreting clones were selected by ELISA.

30 *Purification of recombinant GST-ε-chain fusion proteins from E. coli cell pellets* - This was carried out using procedures described for the purification of recombinant ε-chain fragments expressed in *E. coli* (Helm et al., *supra* (1988)). Frozen cell pellets were defrosted on ice before homogenization (5 fold pellet volume) in 0.05 M Tris-
35 HCl buffer pH 7.9 containing 2 mM EDTA, 0.1 mM dithiothreitol, 1 mM

β -mercaptoethanol, 0.25 M NaCl, 0.1% sodium deoxycholate, 25 μ g/ml PMSF, 5% glycerol. The homogenate were dispersed by sonication before addition of 100 μ g/ml lysozyme and 20 μ g/ml DNAase I. Homogenate were kept on a rotary shaker for 12-15h at 4°C before centrifugation at 10,000g for 10 min. The pellets were washed twice in 20 fold pellet volume of 0.05 M Tris-HCl buffer pH 7.9 containing 1 mM EDTA, 0.1 M NaCl, 25 μ g/ml PMSF. Inclusion bodies from cell pellets were solubilized in 0.05 M Tris-HCl buffer pH 7.9 containing 8 M urea, 1 mM EDTA, 0.1 M NaCl, 25 μ g/ml PMSF and dialyzed for 12h against 200 fold volume of the same buffer omitting urea, but with the addition of 0.1 mM dithiothreitol and 1 mM P-mercaptoethanol. Insoluble materials were removed by centrifugation and 30-75% of recombinant F-chain peptides were found in the supernatant fraction. Affinity purification from this fraction was carried out using a rabbit anti-GST antiserum coupled to Sepharose 4B. The chimeric h/r antibody was purified from cell culture supernatants using NP-specific affinity columns and analyzed by polyacrylamide gel electrophoresis (PAGE) and immunoblotting. See Helm, et al., supra (1988); Helm et al., supra (1991).

Gel electrophoresis and immunoblotting - PAGE and electroblotting procedures have been described before (Helm, et al., supra (1988); Helm et al., supra (1991). Blots were developed with a polyclonal horseradish peroxidase conjugated anti-hIgE antibody (Dako).

Example 3. Ligand binding studies and cell culture

hIgE VNP (Helm et al., supra (1991)) was iodinated as previously described and the conditions for ligand binding and cell culture have been published (Wilson et al., supra). Affinity purified GST-e-chain fusion peptides were iodinated at 0-4°C in 0.4 M phosphate pH 7.4/7.5 using 4.4 μ Ci of Na¹²⁵I and 150-300 μ g of peptide in tubes coated with 40 pg IODO GEN (Pierce). Following a 15 min incubation period, the reactions were terminated by removing fluid from the coated tubes. Each preparation was fractionated on a 140 ml Sephacryl S-200 column (Pharmacia), preequilibrated with binding

buffer (PBS/0.2% BSA pH 7.4), which effects the separation of dimers and monomers. Following γ -counting of collected fractions, peak fractions were pooled, aliquoted and stored at -70°C . Specific activity ranged from 5.8 - 15.5 $\mu\text{Ci}/\mu\text{g}$.

5 The conditions for maintenance of RBL-2H3 cell-lines transfected with the α -chain of hFc ϵ R1 (RBL-2/2/C) have been described. See Wilson et al., *supra*. RBL2/2/C clones were plated into 48 well plates at an initial plating density of 105 cells/well and incubated with 10^{-6}M dexamethasone for 24h at 37°C . In
10 preliminary experiments, RBL-2/2/C cells were incubated with increasing concentrations of ^{125}I labelled ligands (0.1-7.5 pg/ml) to determine the minimum saturation concentrations for Fc ϵ -R1 binding. The proportion of molecules capable of binding to Fc ϵ R1 was 78-91% for ^{125}I -labelled h and h/r IgE VNP, while the bindable portion of the
15 ^{125}I -labelled GST-e226-547, GST-e326-547, GST-e340-547, and GST-e-226-354 was 41%, 56%, 53%, and 27% respectively. The number of rF ϵ e molecules bound per cell was calculated on the basis that GST-e326-547 and GST-e340547 are dimers, while GST-e-226-354 is a monomer.

Non-specific binding was determined using a 50-100 fold molar
20 excess of non-labelled hIgE, and the same amount of GST was used as a negative control. The binding of recombinant proteins to Fc ϵ R1 α was determined indirectly, after correcting for non-specific binding (7-17%), by calculating the percentage inhibition of ^{125}I -IgE bound to cells. To measure the inhibition (IC_{50}) of ^{125}I -IgE binding to RBL-2/2/C
25 or the 8866 lymphoblastoid cell line (Helm et al., *supra* (1993) by native and chimeric h/rIgE VNP, and recombinant ϵ -chain fragments, cells were pre-incubated with a 25, 50, 100, and 200 fold molar excess of each of the unlabelled peptides in $^{125}\mu\text{l}$ binding buffer or, as control, binding buffer alone at 22°C for 1h, before the addition
30 of $50\mu\text{l}$ binding buffer containing $2\mu\text{g}/\text{ml}$ ^{125}I -IgE. After 45 min, the cells were washed twice with 0.5 ml ice cold binding buffer and lysed with 0.5 ml lysis buffer (0.5 M NaOH/1% Triton X-100). Samples (0-25 ml) were removed and counted for 5 min on a LKB1277 γ -counter.

The kinetics of association between RBL-2/2/C cells and ^{125}I -
35 labelled h and h/r chimera, GST-e226-547, GST-e-326-547, GST-e-340-547 ($2\mu\text{g}/\text{ml}$, in binding buffer) and GST-e226-354, ($0.7\mu\text{g}/\text{ml}$, in

binding buffer) were measured at 22°C during the first 300 seconds of incubation at pH 7.4. Rate constants were calculated on the basis that GST-F-226-547, GST-e326-547 and GST-e-340-547 are dimers, while GST-e226-354 is a monomer. The forward rate constant (K^+1) was
5 calculated as $VO/CO \times RO$, where VO represents the initial rate of binding, and CO and RO represent the concentration of ligand and receptor number (-130,000 h α -chains per cell. See Wilson et al., supra. To determine the dissociation rate constant (K^-1), cells were pre-incubated for 1h at 22°C with ^{125}I of the ^{125}I -labelled h, and r
10 IgE, the h/r chimera, GST-e-226-547, GST-e326-547, GST-e340-547 and GST-e226-354/7 (ligand concentration as for the determination of K^+1). Cells were washed twice with 0.5 ml binding buffer before ^{125}I binding buffer containing a 50 fold molar excess of unlabelled hIgE or binding buffer was added. At TO and after 15, 30, 60, 120, and
15 180 min intervals, the cells were washed twice with 0.5 ml ice cold binding buffer, solubilized in 0.5 ml lysis buffer (0.5 M NaOH/1% Triton X-100), and 0.25 ml samples were assayed for cell bound ^{125}I .

The pH optimum for the binding of ^{125}I -labelled hIgE and the GST-e-chain fragments to Fc ϵ R1 was determined by incubating RBL-2/2/C
20 cells (Wilson et al., supra) in 48 well plates 50 mM phosphate buffered saline containing 0.2% BSA (pH range 5.9-8.1) for 10 min at 37° C before adding 50 μ l of 2 μ g/ml ^{125}I -h or rIgE or 0.7 μ g/ml of the ^{125}I -GST-e fragments. Cells were incubated for 30 min and the excess-protein was removed by washing with saline containing 0.2% BSA before
25 measurement of cell bound label. Results were corrected for nonspecific binding.

Potassium iodide titration - The generation of IgE mutant VNpHeCys 328 -> Met has been described. See Helm et al., supra (1991). The conformations of native and mutant (Cys 328 -> Met)
30 recombinant IgE were investigated by comparing their intrinsic fluorescence. Solute quenching of protein fluorescence involved excitation of Trp residues at 297 nm and measurement of emission in the range 300-450 nm. Potassium iodide was added gradually to give a quench profile for each protein. Mathematical analysis was carried
35 out according to the Stern-Volmer Law. See Lehrer, *Methods Enzymol.* 49: 222-226 (1978).

Example 4. Identification of core sequence

The present study focused on the identification of the site(s) that determine the interaction of hIgE with its cellular receptors. The strategies employed for the expression of an overlapping family of chimeric GST-he-chain fusion proteins are outlined in Figure 1. Panels 1A & 1B summarize the receptor binding capacities of the GST-he-chain fusion proteins, that of a chimeric C/7 peptide, and a chimeric h/r IgE molecule. The assignment of biological activities is based on inhibition and direct binding studies detailed in Table 1. In Figure 1, panels C & D show the electrophoretic mobilities of C- and N-terminally truncated recombinant GST-he-chain fusion proteins immunoprecipitated with a rabbit anti-GST anti-serum, followed by PAGE analysis under non-reducing conditions, and immunoblotting with a horseradish peroxidase labelled rabbit anti-IgE serum. As shown in Figure 1C, C-terminal truncation yields a number of F--chain peptides for each construct. As judged by PAGE (Figure 1, panel C) and column chromatography (data not shown), approximately one third of the peptides in each set corresponds to the full length fusion peptide as a monomeric fragment. None of these fragments show any propensity to dimerize, although biologically inactive polymeric aggregates form at concentrations >1.3 mg/ml. A set of identical fragments is observed following analysis under reducing conditions (data not shown). Most of the smaller e-chain fragments represent proteolytic cleavage fragments which are recognized by monoclonal antibodies specific for the Ce2 domain (data not shown). In contrast, deletion of N-terminal sequences gives rise to two e-chain fragments and their apparent molecular weight under nonreducing (Figure 1, panel D) and reducing conditions (data not shown) indicates that they correspond, in almost equal quantities, to monomeric and dimeric GST-he-chain fusion proteins.

The data show that only those polypeptides that contain Ce4 or the homologous Cy3 domain can engage both FceR1 and FceR2 while C-terminal truncation of the e-chain results in elimination of binding to Fce-R2. See Helm et al., *supra* (1988); Vercelli et al., *supra*. As shown in Figure 1 panel 1A, sequences common to all fragments

capable of binding to hFcεR1α comprise residues Pro343-Ser353 in the Ce3 domain. Further deletion from either the C- or N-terminal end beyond these residues is associated with a loss of FcεR1 binding.

As shown in Figure 2 and Table I, GST·e-(340-547) and GST·e-(226-354), which comprise the core peptide, inhibit the binding of hIgE with an IC₅₀ in the nanomolar range. In contrast, blocking of IgE/FcεR1 interaction by the GST controls GST·e-(226-340), GST·e-(355-547), and GST·e-(355-547) cannot be detected even above micromolar concentrations.

As shown in the model structure of hIgE-Fc of Figure 3, this sequence forms a loop that is homologous to the loop in rIgG shown to bind to the neonatal FcγRn. See Burmeister et al., *Nature* 372: 379-384 (1994). A further similarity emerged when we investigated the pH dependency of the binding of hIgE to FcεR1. As shown in Figure 3 two pH optima are observed for the binding of hIgE to FcεR1, and occupancy of the receptor is almost twice as high at pH 6.4 than at 7.4. Although the significance of this is not known, it is tempting to speculate that IgE has evolved the lower pH optimum as a result of its physiological importance in the fight against parasitic infestations in the lumen of the intestine at acid pH.

Data summarized in Table 1 show that N- or C-terminal truncation has a negligible effect on the rate of association of biologically active e-chain fragments with FcεR1. In contrast, the rate of dissociation increases several hundred fold following the deletion of residues from the C-terminal end and, as shown in Figure 3, this is associated with a concomitant decrease in receptor occupancy at pH 6.4. Taken together, these data suggest that His residues in the C-terminal region of the IgE molecule make a contribution towards the maintenance of the high affinity interaction between IgE and FcεR1α since this is largely determined by the slow rate of dissociation of the ligand from the receptor.

The data show that the essential determinant for hIgE/FcεR1 recognition depends on a consecutive sequence comprising eleven amino acids computed to form a loop at the interface between the Ce-3 and Ce-4 domain. These observations exclude any direct contribution of Ce4-specific residues as proposed by Stanworth et al. See Stanworth

et al., supra.; Weetall et al., *J. Immunol.* 145: 3849-54 (1990); and Nissim et al., supra (1991, 1992, and 1993). These results confirm and extend those made by Nissim et al., who demonstrated that the receptor binding site in IgE is located in the Ce3 domain, and differ
5 from the conclusions of Hamburger and Gould et al. Thus, Gould et al., propose that residues 330-334 and 329-340 in the switch region between Ce2 and Ce3 are essential for IgE/FcεRI binding. See Hamburger, *Science* 189: 389-391 (1975) and Gould et al., *Biochem. Soc. Trans.* 21: 968-972 (1993); *Nature* 366, 421-428 (1993). As the
10 results of our study clearly demonstrate, these sequences can be deleted without any major influence on the kinetics of hIgE/FcεRI interaction.

It is interesting to note that the active core sequence identified by us overlaps the hIgE-derived peptide generated by Nio
15 et al., who report its capability to block the binding of antigen-specific IgE to cells expressing FcεRI at concentrations in the mM range. See Nio et al., *Peptide Chemistry* 2, 203-206 (1989).

The results of our study indicate that fragments containing the Ce-2 domain are susceptible to proteolysis (Figure 1, panel C). The
20 inclusion of the protease inhibitor phenyl methyl sulfonyl fluoride (PMSF) during the isolation procedure facilitates the purification of polypeptides that engage FcεR1 and FcεR2.

Sequences N- or C-terminal to this core peptide are necessary to provide structural scaffolding for the maintenance of a receptor
25 binding conformation since the core peptide alone cannot engage the receptor. Deletion of C-terminal, but not N-terminal sequences diminishes receptor occupancy at pH 6.4 and increases the dissociation of the ligand from the receptor, and we conclude that residues, including His, in the C-terminal domain make an important
30 contribution towards the maintenance of the high-affinity of interaction between IgE and FcεR1α. Thus, the sequence herein identified as a core sequence overlaps but is different from those previously identified by others.

TABLE I

*Binding of native and recombinant human and rat
IgE-derived ϵ -chain fragments to hFc ϵ RI α*

The kinetics of association and dissociation of the affinity-purified ligands were determined at 22°C. Kinetic constants and IC₅₀, which represents the concentration at which 50% inhibition of ¹²⁵I-IgE V_{NP}h ϵ binding was obtained, were calculated on the basis that GST · ϵ -(226-547), GST · ϵ -(326-354), and GST · ϵ -(340-547) form dimers, while GST · ϵ -(226-354) is a monomer. Nonbinding ligands used at 10⁻⁵ M showed no binding above background. Data shown represent the calculated mean of experiments carried out in duplicate.

Ligand	k_{+1} $M^{-1} s^{-1}$	k_{-1} s^{-1}	K_d M	IC ₅₀ nM	n
hIgE	3.14×10^5	1.3×10^{-5}	4.1×10^{-11}	14	>8
hIgE re-(341-356)	4.3×10^4	1.7×10^{-5}	3.9×10^{-10}	ND ^a	1
GST ϵ -(226-547)	3.6×10^5	1.6×10^{-5}	4.4×10^{-11}	18	2
GST ϵ -(326-547)	4.1×10^5	2.95×10^{-5}	7.2×10^{-11}	23	2
GST ϵ -(340-547)	4.2×10^5	9.8×10^{-5}	2.3×10^{-10}	34	2
GST ϵ -(226-354)	4.3×10^5	6.02×10^{-3}	1.4×10^{-8}	332	3

^a not determined

Example 5. Anti-oligopeptide polyclonal serum production

Anti-sera from rabbits were obtained by immunization with both constrained and unconstrained oligopeptide. The oligopeptide employed was C L S R P S P F D L F I R K S P T I T S C C. The constrained form was obtained by incubation of 0.5 mg/ml of oligopeptide dissolved in 50 mM ammonium bicarbonate for two hours with stirring at room temperature, and then for 90 hrs. at 4°C. The formation of the constraining disulfide bond and the formation of the oligopeptide loop were followed by mass spectrometry; loop formation occurred after three days of standing. After 90 hrs. the sample was lyophilized. Two rabbits each were used. Rabbits were immunized by subcutaneous injection with 100 micrograms each of oligopeptide suspended in PBS/FCA (PBS = phosphate buffered saline, FCA = Freund's complete adjuvant) (v/v). At two-week intervals, the rabbits

received another dose of immunogen in the same concentration but this time suspended in PBS/FIA (FIA = Freund's incomplete adjuvant) (v/v). After the third and last injection (in PBS/FIA), the serum was screened by ELISA for the presence of polyclonal antibodies against the oligopeptide immunogen. Four days after a final intravenous injection (boost), the blood was collected and left at room temperature until clotted. The serum was collected with a Pasteur pipette followed by centrifugation at 3,000 rpm for 10 min in order to separate remaining erythrocytes. Serum aliquots of 1 ml were transferred to Eppendorf tubes and frozen at -20° C until further use. The titer for the constrained oligopeptide used in ELISA was 1:1000; that for the unconstrained oligopeptide it was 1:100.

Example 6. Inhibition of IgE binding to receptor

Three different parameters were investigated.

(1) RBL-2/2C cells were incubated overnight with 5-hydroxytryptamine (5-HT) and with JW8 IgE (Serotec USA, Wash. D.C.) for 24 hours. See Wilson et al., *supra* (1993a, 1993b). The cells were washed 2 times and challenged with the anti-sera raised against the oligopeptides diluted 1:50, 1:100, 1:250, 1:500, and 1:1000. After 15 min, 5-HT release was determined. No 5-HT release was observed under these conditions. In control experiments, cells were incubated overnight in the same fashion, but challenged on day 2 with either JW8 IgE-specific antigen, i.e. 5-iodo,4hydroxy,3-nitrophenyl linked to human serum albumin (NIP-HSA) or a monoclonal antibody directed against the Ce2 or Ce4 domain, approximately 30% of total cellular 5-HT content was released. This shows that the anti-constrained oligopeptide antiserum does not trigger release of 5-HT by cells sensitized with IgE.

(2) RBL-2/2/C cells were incubated with 5-HT for 24 hrs. after which the cells were washed 2 times as above. 0.5 ug/ml of JW8 IgE was incubated overnight with anti-constrained and unconstrained oligopeptide serum (diluted in buffer 1:5, 1:10, 1:50, 1:100, 1:250). 5-HT release was measured after a 15-min incubation period. No 5-HT release was observed. In control experiments where IgE was incubated overnight in the same fashion with monoclonal antibodies directed

against epitopes on either the Ce2 or Ce4 domain, approximately 30% of total cellular 5-HT content was released when these were added to the cells.

- (3) RBL-2/2/C cells were incubated with 5-HT for 24 hours after which the cells were washed 2 times as before. 0.5 ug/ml of JW8 IgE was incubated overnight with anti-serum against the constrained and unconstrained oligopeptides (diluted in buffer 1:5, 1:10, 1:50, 1:100, 1:250). The IgE and anti-serum were added to the washed cells and these were incubated for 1 hour in a tissue culture incubator. For conditions, see Wilson et al., supra (1993). Cells were washed 2 times with buffer, NIP-HSA was added (10 ng/ml), and 5-HT release measured after 15-min of incubation. No 5-HT release was observed when cells were incubated with the anti-serum against the constrained oligopeptide at dilutions between 1:10 to 1:100. In control experiments, cells sensitized with 0.5 ug/ml NIP-specific JW8 IgE, followed by challenge with NIP-HSA, released approximately 30% 5-HT. Cells that were incubated with the anti-serum against the unconstrained oligopeptide, where this was diluted 1:10, showed a nearly 30% release of 5-HT.
- The formation of the disulfide-constrained oligopeptide was monitored using a V9 platform (Fisons) Electron Spin Resonance spectroscopy with positive electrospray vaporization, where the mobile phase had 50% acetonitrile, 50% water plus 1% formic acid added to the sample mix with approximately 1 ug of oligopeptide. Disulfide bond formation occurred after 3 days standing.

Although the foregoing refers to particular preferred embodiments, it will be understood that the present invention is not so limited. It will occur to those of ordinary skill in the art that various modifications may be made to the disclosed embodiments and that such modifications are intended to be within the scope of the present invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Padlan et al.
- 5 (ii) TITLE OF INVENTION: Inhibition of IgE-Mediated
Allergies By A Human IgE-Derived
Oligopeptide
- (iii) NUMBER OF SEQUENCES: 9
- (iv) CORRESPONDENCE:
- 10 (A) ADDRESSEE: Klarquist Sparkman Campbell Leigh &
Whinston, LLP
- (B) STREET: One World Trade Center
121 S.W. Salmon Street
Suite 1600
- (C) CITY: Portland
- 15 (D) STATE: Oregon
- (E) COUNTRY: U.S.A.
- (F) ZIP: 97204-2988
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: 3.5" Disk
- 20 (B) COMPUTER: IBM-PC compatible
- (C) OPERATING SYSTEM: Windows NT
- (D) SOFTWARE: WordPerfect 7.0/ASCII
- (vi) CURRENT APPLICATION DATA: Filed herewith
- (A) APPLICATION NUMBER:
- 25 (B) FILING DATE:
- (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: U.S. Provisional 60/031,991
- (B) FILING DATE: December 12, 1996
- 30 (viii) ATTORNEY/AGENT INFORMATION
- (A) NAME: David J. Earp, Ph.D.
- (B) REGISTRATION NUMBER: 41,401
- (C) REFERENCE/DOCKET NUMBER: 4239-48989
- (ix) TELECOMMUNICATION INFORMATION:
- 35 (A) TELEPHONE: (503) 226-7391

(B) TELEFAX: (503) 228-9446

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11

5

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:1:

Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser
10 5 10

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

15

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:2:

Cys Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser
5 10 15

20 Pro Thr Ile Thr Ser Cys Cys
20

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

25

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:3:

Cys Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro
30 5 10 15

Thr Ile Thr Cys Cys
20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18
- (B) TYPE: amino acid
- 5 (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:4:

Cys Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr

5

10

15

10 Ser Cys Cys

18

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 16
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:5:

20 Cys Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Cys

5

10

15

Cys

16

(2) INFORMATION FOR SEQ ID NO:6:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30 (ix) SEQUENCE DESCRIPTION: SEQ ID NO.:6:

CGTGAAGATC TTACAGTCGT C

21

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
5 (D) TOPOLOGY: linear
(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:7:
CCTGCCCATG GCTCACCG 18

(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
10 (A) LENGTH: 55
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:8:
15 CCTCGACCTG TATGAAAATG GGACTCCCAA ACTTACCTGT CTGGTGGTGG ACCTG 55

(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 56
(B) TYPE: nucleic acid
20 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:9:
CCATTTTCAT ACAGGTCGAG GGGACTGGGT GGGATTAGGT AGGCGCTCAC CCCTCT 56

What Is Claimed Is:

1. A purified oligopeptide that interacts with the Fce receptor, wherein the oligopeptide comprises the amino acid sequence:

P S P F D L F I R K S.

2. The purified oligopeptide according to claim 1 wherein the oligopeptide is fewer than 50 amino acids in length.

3. The purified oligopeptide according to claim 2 wherein the oligopeptide is 13-27 amino acids in length.

4. The purified oligopeptide according to claim 1, wherein said oligopeptide has been constrained to form a loop structure.

5. A purified oligopeptide comprising an amino acid sequence selected from the group consisting of the sequences set forth in Seq. I.D. Nos. 1-5.

6. A pharmaceutical preparation comprising a purified oligopeptide according to claims 1, 2, 3, 4 or 5.

7. An isolated DNA molecule encoding an oligopeptide according to claims 1, 2, 3, 4 or 5.

8. A biological system that expresses the DNA molecule of claim 7.

9. A biological system according to claim 8, wherein said biological system is a prokaryotic or a eukaryotic cell.

10. A method of preparing an oligopeptide competitor of IgE, comprising:

(a) culturing a prokaryotic or eukaryotic cell according to claim 9, and

(b) purifying said oligopeptide.

11. A competitive binding assay for hIgE wherein the competitor is an oligopeptide according to claims 1, 2, 3, 4 or 5.

12. An antibody raised against a purified oligopeptide according to claims 1, 2, 3, 4 or 5.

13. A pharmaceutical preparation comprising an antibody according to claim 12.

14. A diagnostic method for determining IgE levels in a sample of fluids comprising the steps of:

(a) contacting said sample with an antibody raised against an oligopeptide competitor to IgE; and

(b) precipitating IgE with said antibody.

15. The method of claim 14 wherein the antibody is an antibody raised against a purified oligopeptide according to claims 1, 2, 3, 4, or 5.

16. A diagnostic method of determining available Fcε receptors on the membrane of cells, comprising the steps:

(a) providing a sample of said cells;

(b) providing a labeled oligopeptide competitor to IgE; and

(c) determining the amount of label bound by said cells.

17. A kit for a diagnostic method for determining IgE levels, comprising an antibody of claim 12 and a container for said antibody.

18. A diagnostic kit for determining available Fcε receptors comprising a purified oligopeptide according to claims 1, 2, 3, 4 or 5, and a container for said polypeptide.

19. A method of targeting a cell which expresses FcεR1 receptor, comprising delivering into an organism an oligopeptide according to claim 1.

20. A protein that interacts with the FcεR1 receptor, wherein the protein consists essentially of the amino acid sequence P S P F D L F I R K S.

21. A protein that competes with IgE for the FcεR1 receptor, wherein the protein consists essentially of the amino acid sequence selected from the group consisting of the sequences set forth in Seq. I.D. Nos. 1-5.

22. A protein that competes with IgE for the FcεR1 receptor, wherein the protein consists essentially of:

- (i) an amino acid sequence P S P F D L F I R K S; and
- (ii) constraining residues that flank the amino acid sequence of (i), wherein the constraining residues include cysteine and are within 16 residues N-terminal and 4 residues C-terminal of the amino acid sequence of (i).




FIGURE 2





FIGURE 3



4/4

FIGURE 4



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 7/06, 7/08, 16/42, A61K 39/395, G01N 33/563, 33/68	A3	(11) International Publication Number: WO 98/24808 (43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/US97/22348 (22) International Filing Date: 5 December 1997 (05.12.97) (30) Priority Data: 60/031,991 6 December 1996 (06.12.96) US (71) Applicant (for all designated States except US): THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH [US/US]; Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): PADLAN, Eduardo, A. [US/US]; 4006 Simms Drive, Kensington, MD 20895 (US). BIRGIT, A., Helm [DE/GB]; 3 Hopton House, 27, Collegiate Crescent, Sheffield S10 2BJ (GB). (74) Agent: EARP, David, J.; Klarquist, Sparkman, Campbell, Leigh & Winston, LLP, Suite 1600, One World Trade Center, 121 S.W. Salmon Street, Portland, OR 97204 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 13 August 1998 (13.08.98)
(54) Title: INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE (57) Abstract <p>Peptides are disclosed that are capable of effective recognition of the human IgE Fcε receptor. The peptides partially comprises a fragment of human IgE. By addition of constraining amino acid residues at or near the polypeptides' N- and C-termini, these peptides may be forced to assume a loop configuration. These constrained peptides are useful as competitors of human IgE for the Fcε receptor, and may be used to block the development of type I hypersensitivity.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/22348

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K7/06 C07K7/08 C07K16/42 A61K39/395 G01N33/68
G01N33/563

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	B.A. HELM ET AL: "Identification of the high affinity receptor binding region in human immunoglobulin E" JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 271, no. 13, 29 March 1996, MD US, pages 7494-7500, XP002067058	1-11, 20-22
Y	see the whole document see page 7495, paragraph 1 --- -/-	16,18,19

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

4 June 1998

Date of mailing of the international search report

24.06.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/22348

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GHADERI ET AL: "Epitope mapping of the sites of binding of Fc epsilon within human IgE" MOLECULAR IMMUNOLOGY, vol. 30, no. 18, 1993, pages 1655-1663, XP002067059	11-15, 17,20-22
Y	see the whole document *peptide F39, Table 1* see page 1657, column 1, last paragraph see page 1657, column 2, paragraph 2	16,18,19
X	WO 95 20606 A (PASTEUR MERIEUX SERUMS VACC ;HURPIN CHRISTIAN MARCEL (FR); LATOUR) 3 August 1995	1,5-13
Y	see page 5, paragraph 1 see page 7, paragraph 2 see claims 1,3,24,26,29	16,18,19
X	WANG Y: "PEPTIDES DERIVED FROM IG HEAVY CHAIN CONSTANT REGION INDUCE PROFOUND IGE ISOTYPE-SPECIFIC TOLERANCE" EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 26, no. 5, May 1996, pages 1043-1049, XP000645198 see the whole document *Peptide E*	1,6-11
X	WO 89 04834 A (RESEARCH CORP) 1 June 1989 see the whole document	1,6-11
X	NIO N ET AL: "INHIBITION OF ALLERGIC RESPONSES BY SYNTHETIC IMMUNOGLOBULIN E PEPTIDE FRAGMENTS AND THE DELINEATION OF THE BINDING SITES IN THE IMMUNOGLOBULIN E MOLECULE TO THE FC RECEPTOR" PEPTIDE CHEMISTRY, PROCEEDINGS 29TH SYMPOSIUM ON PEPTIDE CHEMISTRY, TOKYO, OCT. 24-26, 1991, 1987, pages 765-768, XP000654192 *see table 1 - peptide N. 2* see the whole document	1-6
Y	WO 95 25957 A (MERCK & CO INC ;KONTEATIS ZENON (US); SICILIANO SALVATORE J (US);) 28 September 1995 see claim 1	16,18
Y	WO 87 02061 A (BIOTECH RES PARTNERS LTD) 9 April 1987 see claim 1	19

INTERNATIONAL SEARCH REPORT

h. national application No.
PCT/US 97/22348

Box I Observation where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 19 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/22348

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9520606 A	03-08-1995	FR 2715304 A AU 1538895 A	28-07-1995 15-08-1995
WO 8904834 A	01-06-1989	AT 108458 T AU 2802289 A DE 3850654 D DE 3850654 T DK 354489 A EP 0341290 A JP 2502191 T JP 2721256 B US 5693758 A	15-07-1994 14-06-1989 18-08-1994 15-12-1994 19-09-1989 15-11-1989 19-07-1990 04-03-1998 02-12-1997
WO 9525957 A	28-09-1995	US 5614370 A	25-03-1997
WO 8702061 A	09-04-1987	AU 6408586 A EP 0238645 A	24-04-1987 30-09-1987



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 7/06, 7/08, 16/42, A61K 39/395, G01N 33/563, 33/68	A3	(11) International Publication Number: WO 98/24808 (43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/US97/22348 (22) International Filing Date: 5 December 1997 (05.12.97) (30) Priority Data: 60/031,991 6 December 1996 (06.12.96) US (71) Applicant (for all designated States except US): THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH [US/US]; Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): PADLAN, Eduardo, A. [US/US]; 4006 Simms Drive, Kensington, MD 20895 (US). BIRGIT, A., Helm [DE/GB]; 3 Hopton House, 27, Collegiate Crescent, Sheffield S10 2BJ (GB). (74) Agent: EARP, David, J.; Klarquist, Sparkman, Campbell, Leigh & Whinston, LLP, Suite 1600, One World Trade Center, 121 S.W. Salmon Street, Portland, OR 97204 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 13 August 1998 (13.08.98)
(54) Title: INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE (57) Abstract <p>Peptides are disclosed that are capable of effective recognition of the human IgE Fcε receptor. The peptides partially comprises a fragment of human IgE. By addition of constraining amino acid residues at or near the polypeptides' N- and C-termini, these peptides may be forced to assume a loop configuration. These constrained peptides are useful as competitors of human IgE for the Fcε receptor, and may be used to block the development of type I hypersensitivity.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE

This application claims priority from U.S. provisional application serial No. 60/031,991, filed December 6, 1996.

BACKGROUND OF THE INVENTION

Human IgE is believed to provide immunity to parasites. It
5 also mediates Type I hypersensitivity. Type I hypersensitivity is an allergic response leading to the manifestation of such symptoms as hay fever and asthma. Briefly, on encountering an antigen such as pollen, B-cells commence synthesis of antigen-specific IgE. The antigen-specific IgE then binds via its Fc region to cellular class
10 specific receptors and, thereafter, any further encounter with the antigen triggers degranulation of the cells releasing mediators. This is the cause of the acute inflammatory symptoms, hay fever and asthma, typical of Type I hypersensitivity.

Like all immunoglobulin, IgE comprises two heavy and two light
15 chains. The ϵ heavy chain consists of five domains, one variable domain VH, and four constant domains CH1 to CH4. The molecular weight of IgE is about 190,000 kd. The heavy chain is approximately 550 amino acid residues in length.

A 330 amino-acids long polypeptide, corresponding to amino acid
20 residues 218 to 547 of the ϵ heavy chain of IgE was shown to have an inhibitory effect on the release of mediators from human mast cells. The ϵ chain polypeptides apparently form dimers, i.e., two 330 amino acid long chains linked by disulfide bonds. See Nature 315: 577-78 (1985). The numbering of amino acid residues in the chain
25 corresponds to that proposed by Bennich for hIgE. See Bennich, PROGRESS IN IMMUNOLOGY II, Vol. I, at pages 49-58 (1974).

Strategies that block the initial sensitization of target cells with antigen specific IgE have been explored following the demonstration that human (h) myeloma IgE-derived Fc ϵ fragments
30 generated by papain cleavage, comprising h ϵ -chain residues 227-547, can competitively inhibit the binding of IgE to cells expressing high-affinity receptor (Fc ϵ R1). See Stanworth et al., Lancet 2: 17-

20 (1968); Ishizaka et al., *Immunochemistry* 7: 687-94 (1970). This observation initiated the quest for progressively smaller peptides as potential IgE antagonists.

5 More recent studies aimed at the identification of the receptor binding site(s) employed chimeric human/mouse IgE antibodies, ϵ/γ chimeras, site-specific mutagenesis, anti-IgE antibodies, or IgE derived peptides. See Robertson et al., *Mol. Immuno.* 25: 103-108 (1988); Stanworth, et al., *Lancet* 336: 1279-1283 (1990); Nio et al., *Peptide Chemistry* 2: 203-206 (1989); Weetal et al., *J. Immuno.* 145: 3849-3854 (1990); Nissim et al., *EMBO J.* 10: 101-107 (1991); Nissim et al., *Mol. Immuno.* 29: 1065-1072 (1992); Basu et al., *J. Biol. Chem.* 268: 13118-13127 (1993); Nissim et al., *J. Immuno.* 150: 1365-1374 (1993); and Presta et al., *J. Biol. Chem.* 269: 26368-26373 (1994). They indicate that the site(s) in IgE that interact(s) with Fc-receptors depend(s) on structures associated with residues located in the Ce3 domain, although Ce4 involvement has also been invoked. See especially Basu et al., *supra*; Stanworth, et al., *supra* (1988).

Extensive research to date has pointed to a number of apparently contradictory assignments regarding the mode of action and efficacy of such peptides. In part, this can be attributed to the assay employed for the assignation of biological activity. It has been claimed that short peptides containing between 5-76 amino acids, derived from a region spanning amino acids 265-547 of the Fce region will block the binding of human IgE to class-specific high- and/or low-affinity Fc receptors. See Hamburger *Science* 189: 389 (1975); Helm et al., *Nature* 331: 180 (1988); Helm et al., *Proc. Natl. Acad. Sci.* 186: 9465 (1989); Helm et al., *Progress in Allergy and Clinical Immunology* 2: 589 (1992); Weetal et al., *J. Immuno.* 145: 3849 (1990); Nissim et al., *supra* (1991); Nissim et al., *supra* (1992); Nissim et al., *supra* (1993); Basu et al., *supra* (1993); Stanworth et al., *supra* (1990); Robertson et al., *Mol. Immuno.* 25: 103 (1988); Presta et al., *supra*; Nio et al., *supra* (1989); Nio et al., *FEBS Lett.* 319: 225 (1993). Generally, Fce-derived peptides tested for the inhibition of binding of native antigen specific IgE have a lower affinity for the receptor than the native ligand. See Helm et al., *Progress in*

Allergy and Clinical Immunology 2: 589 (1992). They are therefore unlikely to act *in vivo* as effective competitive inhibitors.

SUMMARY OF THE INVENTION

5 An object of the present invention is to provide new oligopeptide(s) that are stable and highly active in anti-allergy treatment. Another object of the invention is to provide a method of preparing the oligopeptide by heterologous expression and isolation. Alternatively, the oligopeptide may be synthesized by known chemical synthetic methods.

10 Still another objective of the invention is to provide antibodies raised against the oligopeptide which can bind and thus inhibit IgE.

It is a further object of the invention to provide a pharmaceutical preparation in which the active ingredient is one of the oligopeptides. The preparation may also include a pharmaceutical carrier to permit clinical administration of the oligopeptide. It is yet another object of the invention to provide a pharmaceutical preparation in which the active ingredient is an antibody raised against one of the oligopeptides of the invention.

20 It is yet another object of the invention to provide a diagnostic method for estimating the level of IgE antibody in a sample. It is still a further object of the invention to provide a method for estimating the level of IgE antibody bound to Fce receptors on FC_ε receptors expressing cells.

25 It is also an object of the present invention to facilitate targeting by drugs or diagnostic agents of cells that bear IgE high-affinity receptors.

In achieving these and other objects, there is provided, in accordance with one aspect of the invention, oligopeptides that
30 interact with the Fce receptor, wherein the oligopeptide comprises:

P S P F D L F I R K S (Seq. I.D. No. 1)

In accordance with another aspect of the invention, there has been provided oligopeptides that interact with the Fce receptor,

wherein said oligopeptide has been constrained to form a loop structure. For example, the oligopeptide can include C L S R at the N-terminal and P T I T S C C at the C-terminal (see Seq. I.D. No. 2).

5 In accordance with another aspect of the invention, there has been provided pharmaceutical preparations comprising an oligopeptide that has been constrained to form a loop structure.

In accordance with a further aspect of the invention, there has been provided DNA molecules encoding the oligopeptide and biological systems that express the DNA molecule. In a preferred embodiment,
10 the biological system is a prokaryotic or eukaryotic cell.

In accordance with still another aspect of the invention, there has been provided methods of preparing an oligopeptide competitor of IgE, comprising: culturing of the prokaryotic or eukaryotic cell and purifying the oligopeptide.

15 In accordance with yet another aspect of the invention above, there has been provided competitive binding assays for hIgE wherein the competitor is the oligopeptide competitor of IgE.

In accordance with still another aspect of the invention, there has been provided antibodies raised against the oligopeptide
20 competitor of IgE.

In accordance with yet a further aspect of the invention, there has been provided pharmaceutical preparations comprising antibodies raised against the oligopeptide competitor of IgE.

In accordance with still a further aspect of the invention,
25 there has been provided diagnostic methods for determining IgE levels in a sample of fluids comprising the steps of:

(a) contacting said sample with an antibody raised against an oligopeptide competitor to IgE; and

(b) precipitating IgE with said antibody.

30 In accordance with yet another aspect of the invention, there has been provided diagnostic methods for determining available Fcε receptors on the membrane of cells, comprising the steps:

(a) providing a sample of such cells;

(b) providing a labeled oligopeptide competitor to IgE; and

35 (c) determining the amount of label bound by said cells.

In accordance with still another aspect of the invention, there has been provided methods for targeting a cell which expresses FcεR1 receptor, comprising delivering an oligopeptide according to the present invention to an organism.

5 Kits for performing the above methods also are provided.

Proteins that interact with the FcεR1 receptor, wherein the proteins comprise the amino acid sequence P S P F D L F I R K S (Seq. I.D. No. 1), are provided. Also provided are proteins that compete with IgE for the FcεR1 receptor, wherein the proteins comprise C L S
10 R P S P F D L F I R K S P T I T S C C (Seq. I.D. No. 2). Proteins that compete with IgE for the FcεR1 receptor, wherein the protein consists essentially of (i) an amino acid sequence P S P F D L F I R K S, and (ii) constraining residues that flank the amino acid sequence of (i), wherein the constraining residues include cysteine
15 and are within 16 residues N-terminal and 4 residues C-terminal of the amino acid sequence of (i), also are provided.

These and other aspects of the invention will become apparent to the skilled person in view of the disclosure and data contained herein.

20

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Gene constructs, expression products, and mapping of receptor binding regions in human IgE. Recombinant ε-chain gene fragments were subcloned into the multiple cloning site (MCS) of the bacterial expression plasmids pGEX-3X and pGEX-KG and expressed in *E. coli*. See Ho et al., *Gene (Amst.)*, 52: 2940-2948 (1989), Helm et al., *supra* (1988), and Helm et al., *Eur. J. Immuno.* 21: 1543-1548 (1991). The ε-chain expression plasmids pSV-V_{NP}he/re were employed for the construction of mutant and chimeric IgE molecules and expressed in the J558L myeloma cell line. See Helm et al., *supra*
25 (1991). Panels A and B summarize the ability of the truncated, chimeric, and mutant ε-chain variants to bind to FcεRIα expressed on RBL-2H3.1 and RBL-2/2/C cells and to FcεRII expressed on the 8866 lymphoblastoid cell line. See Wilson et al., *Eur. J. Immuno.* 23: 240-244 (1993) and Helm et al., *supra* (1991). Initial screening for
30

biological activity was determined by assessing the capacity of GST·e-chain fusion proteins to inhibit the binding of ¹²⁵I-labeled hIgE (1 nM) to the receptors. For a description of GST·e-chain fusion proteins see Helm et al., *J. Biol. Chem.* 271: 7494-7500 (1996). The degree of inhibition effected by nonbinding ligands was identical, within limits of experimental error, to that observed with GST, which was included as a negative control (see Figure 2). Purification of truncated recombinant GST·e-chain fusion proteins and mutant and chimeric IgE molecules was carried out as described in Examples. Ligands were labeled with ¹²⁵I for direct binding studies (see Table I). Nonbinding ligands showed no binding above background levels even at concentrations above 10⁻⁵ M. Panels C and D show GST·e-chain fusion proteins that were immuno precipitated with a rabbit anti-GST serum, followed by SDS-PAGE (12%) separation under nonreducing conditions and immunoblotting with a horseradish peroxidase-labeled rabbit anti-human IgE serum. Panel C, lanes 1-6, GST·e-(226-547), GST·e-(226-361), GST·e-(226-357), GST·e-(226-354), GST·e-(226-352), GST·e-(226-340), Panel D, lanes 1-6, GST·e-(326-547), GST·e-(340-547), GST·e-(343-547), GST·e-(345-547), GST·e-(350-547), GST·e-(226-440)-Cy3. +, receptor binding; -, loss of receptor binding; n.d., not determined.

Figure 2. Percentage of inhibition of ¹²⁵I-hIgE binding to RBL-2/2/C cells by native and recombinant hIgE-derived e-chain fragments. To measure the inhibition (IC₅₀) of ¹²⁵I-hIgE to RBL-2/2/C cells by native IgE and recombinant e-chain fragments, cells were preincubated at 22°C for 1 h with increasing concentrations (10⁻¹² - 10⁻⁵ M) of each of the unlabeled GST fusion peptides in 125 µl of binding buffer or, as a negative control, GST or binding buffer. ¹²⁵I-hIgE was then added (1 nM). After 45 min. the cells were washed twice with 0.5 ml of binding buffer and lysed in the same volume of lysis buffer, and aliquots were removed for γ-counting. The IC₅₀ values for GST·e-(226-547) and GST·e-(226-357) (data not known) were identical to those observed for hIgE (▲) and GST·e-(226-354) (Δ). In GST·e-(226-340) and GST·e-(335-547), the sequence common to all fragments that can engage FcεRI has been deleted by either the N- or C-terminal truncation. GST·e-(226-340) (◇) and GST·e-(335-547) (■)

show inhibition levels similar to that obtained with GST (\square) and all other fragments classified as nonbinding ligands in Figure 1. \blacklozenge , GST·e-(340-547); \circ , GST·e-(440-547). Data shown represent the means of at least three separate experiments carried out in duplicate.

5 Figure 3. Drawing of the α -carbon trace of a model structure for hIgE with various fragments and domains indicated. The light chains are drawn with thin lines and the heavy chains with thick lines, one thicker than the other. The interchain Cys at position 328 is labeled. The 11-amino acid segment 343-353, which is common
10 to all IgE-derived peptides that bind to Fc ϵ RI, is drawn with larger circles and wide, empty bonds in heavy chains.

Figure 4. pH profile for the binding of native IgE and recombinant IgE-derived peptides to RBL-2/2/C cells. h α -chain-transfected RBL-2/2/C clones were distributed into 48-well plates at
15 10^5 cells/well and incubated with 10^{-6} M dexamethasone for 24 h at 37°C. Prior to the assay cells were washed twice with 0.5 ml of saline containing 0.4% BSA and preincubated with 125 μ l of 50 mM phosphate-buffered saline containing 0.4% BSA (pH range 5.9-8.1) for
20 10 min at 37°C before adding 50 μ l of 2 μ g of 125 I-labeled IgE (\square), 0.7 μ g of GST·e-(340-547) (\blacklozenge), and GST·e-(226-354) (\square). Cells were incubated for 30 min, after which unbound ligand was removed by washing with binding buffer before measurement of cell-bound label. Results were corrected for nonspecific binding. (Data shown represent the means of two determinations carried out in duplicate.)

25 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

1. Definitions

Core Sequence: In the present invention, "core sequence" refers to an 11 amino acid sequence which has been identified as the minimal region of IgE required for interaction with Fc ϵ receptors.

30 Constrained: In the present invention, a "constrained" molecule is a short molecule, typically an oligopeptide, comprising residues that affect the shape of the oligopeptide. The constraint is introduced by residues near or at the ends of the oligopeptide. Such residues link to each other, generally by forming disulfide
35 bonds which constrain the shape of the molecule into a loop-like

structure. Often the residues involved in creating a constraint are cysteines.

Loop Configuration: Model studies have suggested that the IgE region that interacts with the Fce receptor forms a loop-like structure. See Helm et al., *supra* (1991) and Padlan & Helm, *Biochem. Soc. Transactions* 21: 963-967 (1993). According to this description, "loop" refers to a native-like configuration achieved by an oligopeptide comprising the core sequence and further constrained as above, so that the ends of the oligopeptide are in close proximity.

Residue: The IgE competitor molecule of the invention includes oligopeptides. Its constituents or chemical entities (its subunits) of the competitor molecule typically are amino acids. According to some embodiments, however, other entities can be introduced into what is still called an "oligopeptide" in this description. Those may be modified amino acids or other groups possessing desired features. For example, any chemical residue that has a carboxyl group may allow formation of a covalent bond to another molecule. Also, some non amino acid residues, such as methylene, carboxymethylene, and carboxidiimide, may allow disulfide-like bonds within the oligopeptide.

Oligopeptide: The oligopeptide of the present invention is defined as a molecule of about 50 residues or smaller. Part of the sequence of this molecule is the core sequence defined above. The oligopeptide is constrained as defined above, by additional residues.

2. Overview

It has been discovered for the first time that a particular peptide, Pro343-Ser353, is common to all polypeptides that can bind the high- and low-affinity IgE receptors. An understanding of the native structure of the binding domain by three-dimensional modelling of the binding site for IgE was developed. These studies have provided information regarding the structural motif that is required for an oligopeptide to be effective in mimicking IgE in its interaction with class-specific Fc receptors. Based on those findings, model constrained oligopeptides were proposed and tested for binding Fce receptors. The testing of those oligopeptides

includes a determination of the rate of association and disassociation to receptors, and their ability to compete with IgE. Methods for testing such activity have been described. See Wilson et al., *supra*; Wilson et al., *J. Clin. Immunoassay* 16: 91-95 (1993); and Helm et al., *supra* (1991).

A useful oligopeptide would be relatively small, so that it will be easy to synthesize and deliver. An additional advantage of a small but effective oligopeptide is that its therapeutic/prophylactic use is less likely to trigger an adverse, i.e. anaphylactic, immune response.

However, a small peptide might not assume the structure of the segment as found in the intact molecule. The three-dimensional structure of a polypeptide is determined by its amino-acid sequence and its environment and conformation. Fragments which are too small will not have the environment found in the intact molecule. Such fragments, freed from structural constraints, will assume many other conformations. See Wright et al., *Biochem.* 27: 7167 (1988). The probability that a peptide will assume the proper conformation, i.e. that which is found in the intact molecule is very small. Improper configuration will likely be manifested in a greatly reduced binding affinity. Low binding affinities will require the administration of large doses of peptide for effectiveness. This difficulty can be obviated by imposing structural constraints on the peptide segment.

According to one embodiment of the invention, a molecule was designed that comprises the core sequence that is required for the binding of IgE to its receptors. This embodiment is further constrained so that its structure mimics that which has been predicted for the segment as found in the intact IgE molecule. The sequence is:

C L S R P S P F D L F I R K S P T I T S C C (Seq. I.D. No. 2).

The oligopeptide of the embodiment thus comprises an IgE derived sequence extending past the core sequence: L S R P S P F D L F I R K S P T I T which is the Leu340-Thr357 fragment from the human IgE sequence, and additional amino acids at the N- and C- termini of the peptide. In those sequences, the Pro343-Ser353 core fragment P S P F D L F I R K S (Seq. I.D. No. 1) is underlined.

In the one embodiment, the Ser after Thr357 was added to improve the solubility of the peptide; other amino acids, such as Thr, Asp, Asn, Glu, Gln, Tyr, or His could have been used also. The starting and penultimate Cys were added to provide the intramolecular disulfide linkage. Thus the oligopeptide forms a loop and is active only when incubated under conditions that promote disulfide bond formation. The C-terminal cysteine was added for possible linkage to a carrier molecule or pharmacologically active agent; such linkage may not be needed or desired, depending on the chosen application or mode of administration of the oligopeptide. Other amino acids could be used to link to a second molecule and may be introduced at either the N- or the C-terminus.

In other embodiments, longer or shorter oligopeptides which contain the residues required for binding to receptor, likewise constrained by disulfide bonds or the like, also will be effective. Examples of shorter, constrained oligopeptides are:

C S R P S P F D L F I R K S P T I T C C (Seq. I.D. No. 3)
 C R P S P F D L F I R K S P T S C C (Seq. I.D. No. 4)
 C P S P F D L F I R K S P T C C (Seq. I.D. No. 5)
 where the underlined sequence is the core sequence required for binding the receptor.

According to other embodiments, the terminal Cys may or may not be needed or desired, depending on whether the oligopeptide is to be linked to an additional effector molecule or not. In yet other embodiments, other amino acids may be substituted for residues outside the recognition motif, or within the recognition motif, to improve the solubility or other physical chemical property of the oligopeptide or to enhance its biological activity. Very small insertions or deletions (usually no more than a few amino acids) are also possible. Shorter and longer polypeptides may allow folding such that the core sequence is in a configuration like the native configuration. However, practically speaking, peptides outside certain lengths are less likely to achieve the desired configuration. In a preferred embodiment, the oligopeptide is fewer than 50 and more preferably 13-27 residues in length. Furthermore, other means of

constraining the recognition peptide to its loop-like conformation as found in the intact molecule may be used also.

Other chemical structures could be utilized to constrain the oligopeptide. For example, linkages involving methylene, carboxymethylene, carboxidiimide fragments, etc. have been utilized. See for example Dutta et al, *J. Med. Chem.* 33: 2552-2560, 2560-2568 (1990); Sham et al, *J. Med. Chem.* 31: 284-295 (1988); Thaisrivongs et al., *J. Med. Chem.* 31: 1369-1376 (1988), and 34: 1276-1282 (1991); Weber et al., *J. Med. Chem.* 34: 2692-2701 (1991). It may also be desirable to replace groups inside or outside the receptor motif with peptidomimetic or other moieties for the purpose of improving the binding properties of the molecule, or its physical chemical properties. Such changes would result in an oligopeptide that adheres to the principles of the present invention and thus are within the scope of the invention.

Exemplary uses for an oligopeptide that mimics the epsilon (ϵ) heavy-chain region of IgE include the capacity (a) to inhibit the binding to class-specific receptors and thus prevent the release of cellular mediators from cells expressing the receptors, (b) to stimulate the formation of non-anaphylactic anti-IgE antibodies which can bind to membrane IgE and inhibit B-cell synthesis of IgE by down regulation of its synthesis, (c) when linked to a pharmacologically active agent, to selectively destroy cells expressing Fc ϵ receptor-bearing cells, and (d) to inhibit IgE/CD23 facilitated antigen presentation. The oligopeptide thus can be used prophylactically or as a treatment. In addition, the constrained oligopeptide can be used in vitro to determine receptor availability and receptor occupancy by IgE. In such tests, the polypeptide, or IgE, can be labeled to enhance detection.

An antibody raised against such an oligopeptide also has utility due to its interception of IgE in the plasma, away from the Fc ϵ receptor. Antibodies raised against the oligopeptide, as opposed to an anti-Ab antibody, are likely to display less cross-reactivity. Furthermore, antibodies raised against antibodies can sometimes mimic the original antigen and worsen the hypersensitivity state. Antibodies raised against the oligopeptide of the invention reduce

the risk of increasing hypersensitivity, since they do not recognize receptor bound IgE. The antibody can inhibit IgE/CD23 facilitated antigen presentation, and, when linked to a pharmacologically active agent, can selectively destroy cells expressing membrane IgE.

5 According to one aspect of the invention, antiserum is raised against any of the oligopeptides of the invention. According to one embodiment, polyclonal or monoclonal antibodies, including humanized antibodies are prepared. Such antibodies are used as a prophylactic or therapeutic treatment, by virtue of their binding to IgE in the
10 plasma but not to IgE bound to cellular receptor.

 According to one embodiment of the invention, sera was raised against the oligopeptide: C L S R P S P F D L F I R K S P T I T S C C (Seq. I.D. No. 2). It was shown that only oligopeptide pre-incubated under conditions that allow S-S bridges to form produced sera which
15 can bind IgE in solution. Furthermore, the sera did not produce hypersensitivity. The antibody appears not to bind IgE when IgE is bound to the Fcε receptor.

 It is well known that IgE plays a role in the response of an organism to parasites. See Hagan et al., *Nature* **349**: 243-45 (1991).
20 Furthermore, high levels of IgE have been correlated with AIDS. See Wright et al., *J. Allergy Clin. Immun.* Feb: 445-52 (1990), and Lin et al., *Ann. Allergy* **61**: 269-72 (1988). Thus, determination of either the IgE titer in a sample, or the level of expression or availability of Fcε receptor on cell surface would be desirable. Hence, labeled
25 antibody raised against the constrained oligopeptide of the invention and the constrained oligopeptide itself, have useful application in diagnostic assays. According to one embodiment of the invention, the oligopeptide can be used to determine the level of expression of IgE receptors and/or the levels of receptor available to bind IgE.
30 According to another embodiment, the titer of IgE in a sample can be estimated by employing antibody specific for the constrained oligopolypeptide.

3. A DNA Molecule Encoding the Oligopeptide of the Invention

 According to one object of the invention, an oligopeptide is
35 provided which mimics IgE in its ability to bind Fcε receptor.

According to one embodiment, the oligopeptide comprises Cys residues near the termini which constrain and thus shape a polypeptide into the desired configuration by providing intramolecular S-S bonding, i.e. forming a loop. According to a preferred embodiment, the oligopeptide further comprises additional amino acids which either do not affect its activity, or impart benefits, such as improved solubility, stability or an optimum size. According to a further preferred embodiment, a C-terminal or N-terminal amino acid is added to allow for covalent linkage of the oligopeptide to another molecule. The oligopeptide thus designed could be chemically synthesized. Chemical synthesis of peptides is well known to an artisan skilled in the field. It could allow the introduction of modified amino acids, or linkage of groups other than an amino acids.

However, in a preferred embodiment, the oligopeptide according to any of the embodiments above is a translation product of a gene encoding the oligopeptide. The gene, and the variations of the gene according to the embodiments above, can be produced by many methods. For example, a set of complementary oligonucleotides could be designed. If need be, "batch ligation" of sets of such oligonucleotides could be employed. That is, if the coding region is too long to be covered by one set of complementary oligonucleotides, ligation of sets of complementary oligonucleotides can be employed. In either case, the oligonucleotides would be so designed as to allow subsequent subcloning into an expression vector.

Alternatively, one can take advantage of the fact that this segment has been cloned and expressed as a GST fusion peptide which does not form a loop. See Helm et al., *supra* (1996). PCR or NASBA could be applied, employing mutagenic primers, so a subsection of the DNA containing changes would be amplified and subcloned. Yet another alternative would be that a section of interest from the gene would be subcloned (by amplification as above, or by the "cut and paste" of molecular cloning) into a vector that can produce single stranded DNA. This would facilitate employment of mutagenic primers, employing well known techniques and commercially available kits. Finally, combinations of the above methods, to allow further

variation of a gene sequence encoding the desired oligopeptide, could be employed by one skilled in the art. The changes envisioned, at the protein level, could result in substitution, insertion or deletion of a few amino acids.

5 Substitutional variants typically contain the exchange of one amino acid for another at one or more sites within the protein, and are designed to modulate one or more properties of the protein such as stability against proteolytic cleavage. Substitutions could be conservative, that is, one amino acid is replaced with one of similar
10 shape and charge. Conservative substitutions are well known in the art and include, for example, the changes of: alanine to valine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; histidine to asparagine or glutamine; isoleucine to
15 leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine, or glutamate; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine.
20 Changes involving less conservative substitutions also can be made according to the invention.

 Insertional variants may alter the sequence of the oligopeptide competitor of IgE or may be used to create fusion proteins such as those used to allow rapid purification of the protein (see below).
25 Insertional variants may also produce hybrid proteins containing sequences from other proteins. Other insertional variants can include those in which additional amino acids are introduced within the coding sequence of the protein. These typically are smaller insertions than the fusion proteins described above and are
30 introduced, for example, to disrupt a protease cleavage site or modify chemical or biological properties of the oligopeptide. Deletional variants would remove one or a few amino acids from the oligopeptide.

 In one embodiment, peptides produced from translation of a gene
35 are subjected to further chemical manipulation, so modification of the peptide is achieved.

The methods employed to introduce such changes are well known in the art. Some often-used manuals describing relevant experimental protocols and techniques are Ausubel, ed., in CURRENT PROTOC. MOLEC. BIOL., vols. 1-3, Wiley Interscience Publ., and also Murray ed.,
5 METH IN MOLEC. BIOL., especially vol. 7, GENE TRANSFER AND EXPRESSION PROTOC., (1991); vol. 9, PROTOC. IN HUMAN MOL. GENE., Mathew ed., (1991); and vol. 15, PCR PROTOC., White ed., (1993), Humana Press, Totowa, NJ. See also U.S. Patent No 5,409,818.

4. *Expression and Purification of the oligopeptide*

10 According to another embodiment of the invention, a DNA encoding an oligopeptide sequence as described above is used to recombinantly produce protein. For this purpose, the DNA is operably linked into a vector to transcriptional/translational features, according to methods well understood by those skilled in the art.
15 Typically, the DNA sequence encoding a protein/peptide product will be inserted downstream from a promoter. Downstream of the coding sequence there will be a terminator sequence. In general, host-cell specific sequences improving the production yield will be used and appropriate control sequences will be added to the expression vector,
20 such as ribosome binding sites, and, in eukaryotes, enhancer sequences, and polyadenylation sequences. The construct can be expressed in a variety of systems; for example in mammalian cells, baculoviruses, bacteria and yeast, as discussed below.

Each such host system would have advantages and disadvantages to be considered in any given circumstance. For example, bacterial
25 expression would be easy, inexpensive and efficient. Proper folding or modifications, or potentially of more immediate interest in the present invention, disulfide bond formation *in vivo*, would necessitate use of eukaryotic cell systems. Those choices are
30 rationally made by the skilled artisan in light of the specific gene fragment to be expressed, and its ultimate use. Vectors for expression in each such host are commercially available.

Thus, the present invention also relates to a host cell stably transformed with any of the above described DNAs of the invention,
35 wherein the transforming DNA is capable of being expressed. Such

host cell can be a prokaryote or eukaryote. Preferred host cells include bacterial, insect, mammalian and yeast cells, or whole organisms such as insects or plants. Methods for the transformation of such host cells with the DNA of the present invention and methods
5 of culturing the same would be well-known to the skilled artisan.

In a preferred embodiment, oligopeptides according to the invention are cloned and expressed in *Escherichia coli* (*E. coli*). Larger e chain fragments are known to express in *E. coli*. See *Eur. J. Immuno.* 15: 966-69 (1985); and *Proc. Nat'l Acad. Sci. USA* 81:
10 2955-59 (1984). Furthermore, small peptides have been expressed as GST fusion peptides which could be cleaved from GST by thrombin. See Helm et al., *supra* (1996).

5. Antibody Production and Related Methods

Antibodies against the oligopeptide of the invention can be
15 obtained using the product of an expression vector as an antigen. The preparation of polyclonal antibodies is well-known to those of skill in the art. See, for example, Green, "Production of Polyclonal Antisera," in *IMMUNOCHEMICAL PROTOCOLS*, Manson, ed., pages 1-5, Humana Press (1992). In a preferred embodiment, rabbit polyclonal
20 sera was prepared against one of the oligopeptides of the invention.

Alternatively, an anti-oligopeptide antibody of the present invention may be derived from a rodent monoclonal antibody (MAb). Rodent monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art. See, for example, Kohler
25 and Milstein, *Nature* 256: 495 (1975), and Coligan (eds.), *CURRENT PROTOCOLS IN IMMUNOLOGY*, VOL. 1, pages 2.5.1-2.6.7 (John Wiley & Sons 1991). Briefly, monoclonal antibodies can be obtained by injecting mice with a composition comprising an antigen, verifying the presence of antibody production by removing a serum sample, removing the
30 spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to the antigen, culturing the clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.

MAbs can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography. See, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3. Also, see Baines et al., "Purification of Immunoglobulin G (IgG)," in *METHODS IN MOLECULAR BIOLOGY*, VOL. 10, pages 79-104 (The Humana Press, Inc. 1992).

An anti-polypeptide antibody of the present invention may also be derived from a primate. For example, general techniques for raising therapeutically useful antibodies in baboons may be found, for example, in Goldenberg, international patent publication No. WO 91/11465 (1991), and in Losman et al., *Int. J. Cancer* 46: 310 (1990).

Alternatively, a therapeutically useful anti-oligopeptide antibody of the present invention may be derived from a "humanized" monoclonal antibody. Humanized monoclonal antibodies are produced by transferring mouse complementarity determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, and then, substituting human residues in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by the publication of Orlandi et al., *Proc. Nat'l Acad. Sci. USA* 86: 3833 (1989), which is incorporated by reference in its entirety. Techniques for producing humanized MAbs are described, for example, by Jones et al., *Nature* 321: 522 (1986), Riechmann et al., *Nature* 332: 323 (1988), Verhoeyen et al., *Science* 239: 1534 (1988), Carter et al., *Proc. Nat'l Acad. Sci. USA* 89: 4285 (1992), Sandhu, *Crit. Rev. Biotech.* 12: 437 (1992), and Singer et al., *J. Immuno.* 150: 2844 (1993).

As an alternative, an antibody of the present invention may be derived from human antibody fragments isolated from a combinatorial immunoglobulin library. See, for example, Barbas et al., *METHODS: A Companion to Methods in Enzymology* 2: 119 (1991), and Winter et al.,

Ann. Rev. Immuno. 12: 433 (1994), which are incorporated by reference. Cloning and expression vectors that are useful for producing a human immunoglobulin phage library can be obtained, for example, from STRATAGENE Cloning Systems (La Jolla, CA).

5 In addition, antibody of the present invention may be derived from a human monoclonal antibody. Such antibodies are obtained from transgenic mice that have been "engineered" to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain locus are introduced into
10 strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy chain and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human
15 antibodies from transgenic mice are described by Green et al., *Nature Genet.* 7: 13 (1994), Lonberg et al., *Nature* 368: 856 (1994), and Taylor et al., *Int. Immuno.* 6: 579 (1994).

6. The oligopeptide as a Targeting Molecule

The oligopeptide of the invention, when covalently bound or
20 simply associated to another agent, could, by virtue of its affinity for the FcεR1, deliver such other agent to a cell that expresses the receptor. In the examples given herein, a Cys at the C-terminus of the oligopeptide is designated to facilitate just such association. Such agent could include for example a drug, a radiolabeled molecule,
25 or any agent that could be diagnostic, or therapeutic, or used as a research tool. For example, liposomes are one method of delivery of agents to cells in an organism. They are sometimes targeted to the cell type or tissue of interest by the addition to the liposome preparation of a ligand, usually a polypeptide, for which a
30 corresponding cellular receptor has been identified. Examples of cell receptors previously targeted include the folate receptor, which has recently been identified as a prominent tumor marker, especially in ovarian carcinomas. KB cells are known to vastly overexpress the folate receptor. See Campbell et al., *Cancer Res.* 51: 6125-32
35 (1991). Yet other targeting ligands have been examined for liposome

targeting including transferrin, protein A, ApoE, P-glycoprotein, α_2 -
macroglobulin, insulin, asialofetuin, asialoorosomucoid, monoclonal
antibodies with a variety of tissue specificities, biotin, galactose-
or lactose- containing haptens (monovalent and tri-antennary),
5 mannose, dinitrophenol, and vitamin B12. The ligands are covalently
conjugated to a lipid anchor in either pre-formed liposomes or are
incorporated during liposome preparation. See Lee & Low, *J. Biol.*
Chem. 269: 3198-04 (1994); *Biochim. Biophys. Acta* 1233: 134-44
(1995).

10 In one embodiment of the invention, the association of the
oligopeptide of the invention with a delivery agent as described
above includes association with additional targeting agents. For
example, in order to gain access to the cytoplasm, the DNA molecule
must overcome the plasma membrane barrier. In nature, viral fusion
15 peptides facilitate the delivery of viral DNA into the cytoplasm by
promoting viral membrane fusion with the plasma membrane. For recent
reviews on this subject, see Stegmann et al., *Ann. Rev. Biophys.*
Chem. 18: 187-221 (1989). For the influenza virus, the hemagglutinin
(trimer) HA peptide N-terminal segment (a hydrophobic helical
20 sequence) is exposed due to a conformational change induced by acidic
pH in the endosome (pH 5-6), inserts into the target membrane, and
mediates the fusion between the virus and the target endosomal
membrane. See Weber et al., *J. Biol. Chem.* 269: 18353-58 (1994).
Recently, several amphipathic helix-forming oligopeptides have been
25 designed to imitate the behavior of the viral fusion peptide. See,
for example, Haensler & Szoka, *Biocon. Chem.* 4: 372-79 (1993).

Nuclear localization signal peptides, when attached covalently
to a macromolecule such as a protein, have been shown to facilitate
their translocation into the nucleus. See Goldfarb et al., *Nature*
30 322: 641-44 (1986); Shreiber et al., *Med. Sci.* 8: 134-39 (1992). By
the combination of cellular targeting by the oligopeptide of the
invention and nucleus targeting, yet other agents could be delivered
in the nucleus of specific cells, for example DNA molecules.

7. *Delivery of the Therapeutic Agents to a Patient*

Delivery of any of the above therapeutic agents or antibodies requires administration to the patient of therapeutically effective doses. "Administering" the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan.

The pharmaceutical compositions are preferably prepared and administered in dose units. Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the patient, different daily doses are necessary. Under certain circumstances, however, higher or lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and also by multiple administration of subdivided doses at specific intervals.

The pharmaceutical compositions according to the invention are preferably administered intravenously. However, other routes of administration can be readily ascertained. Thus, the pharmaceutical compositions can be administered topically, intravenously, orally or parenterally or as implants, even rectal use as appropriate. Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizers are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of present methods for drug delivery, see Langer, *Science*, 249: 1527-1533 (1990), which is incorporated herein by reference.

The pharmaceutical compositions according to the invention may be administered locally or systemically. By "therapeutically

effective dose" is meant the quantity of a compound according to the invention necessary to prevent, to cure or at least partially arrest the symptoms of the disease and its complications. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the patient. Typically, dosages effective *in vitro* may provide useful guidance in the amounts useful for *in situ* administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various considerations are described, e.g., in Gilman et al. (eds.) (1990) GOODMAN AND GILMAN'S: THE PHARMACOLOGICAL BASES OF THERAPEUTICS, 8th ed., Pergamon Press; and REMINGTON'S PHARMACEUTICAL SCIENCES, 17th ed. (1990), Mack Publishing Co., Easton, Pa.

The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration and are not intended to limit the present invention.

Example 1. Gene constructs and site specific mutagenesis

The numbering scheme for heavy-chain amino acid residues used in previous publications has been maintained. See Helm et al., *supra* (1988); Vercelli et al., *Nature* 338: 649-652 (1989); Helm et al., *supra* (1989); Helm et al., *supra* (1991). Herein, "h" stands for human and "r" stands for recombinant. The polymerase chain reaction (PCR) was used to amplify heavy-chain fragments comprising the entire Fc region (226-547), the C γ 3 from mouse IgG2a, the C ϵ 2 domain (226-329), and the C ϵ 4 domain (440-547). N-terminal deletions of the Fc region were prepared starting at amino acid residue positions 326, 330, 340, 342, 343, 344, 345, 350, and 355 and terminating at residue 547. C-terminal deletions were prepared starting at amino acid residue 226, and terminating at residues 361, 357, 354, 353, 352, 345 and 340. The DNA products were purified by agarose gel electrophoresis, digested with appropriate restriction enzymes, and subcloned into the bacterial expression plasmids pGEX-3X and pGEX-KG, which direct the synthesis of foreign polypeptides in *E. coli* as fusions with the 26 kDa glutathione-S-transferase (GST). See Guan et al., *Anal. Biochem.*

192: 262-267 (1991). Cloning the recombinant ϵ -chain fragments in frame to the 3' end of the GST gene facilitates the production of large amounts of fusion protein (-500 mg/L). In addition to a versatile multiple cloning site, the vectors have been engineered so that the GST carrier can be cleaved off by digestion with coagulation factor Xa or thrombin. The initial screening for receptor blocking activity was carried out with partially purified GST- ϵ -chain fusion polypeptides. Following affinity purification on rabbit anti-GST affinity columns, and GST removal with thrombin, ϵ -chains showed identical receptor blocking capacities when compared to GST- ϵ -chain fusion polypeptides. Therefore this step was eliminated and all assays described in this study were carried out with affinity purified GST- ϵ -chain fusion polypeptides. Short GST fusion peptides comprising ϵ -chain residues 338-359 and 340-357 were also generated. Site-specific mutagenesis was performed by overlap extension PCR (Ho et al., supra). Bacterial strains used as host for transformation were JM109 or MC1061.

For the construction of the chimeric h/r IgE molecule we employed the ϵ -chain expression plasmids PSV-VNphe/re Helm et al., supra (1991). A construct where the sequence known to be essential for hFc ϵ R1 interaction has been replaced by the homologous rat sequence encoding residues 341-356 was also generated by overlap extension PCR. See Ho et al., supra. The template for PCR was a 3.4 kb IgE C ϵ ₁₋₄ genomic DNA cassette cloned into the BamHI site in pUC19 (pHe). A 719 bp fragment coding essentially for C ϵ 2-3 was generated by PCR.

This involved PCR reactions employing four primers, two external primers 5'- CGTGAAGATCTTACAGTCGTC -3' (Seq. I.D. No. 6) and 5'- CCTGCCCCATGGCTCACCG -3' (Seq. I.D. No. 7), and two internal primers 5'- CCTCGACCTGTATGAAAATGGG ACTCCCAAACTTACCTGTCTGGTGGTGGACCTG -3' (Seq. I.D. No. 8) and 5'- CCATTTTCATACAGGTCGAGGGGACTGGGTGGGATTAGGTAGGCG-CTCACCCCTCT -3' (Seq. I.D. No. 9). The external primers had Bgl II and Nco I restriction enzyme sites build in the sequence, respectively. For each PCR reaction, mixtures contained 200 ng of template, 2 μ g of each primer, 1 mM dNTPs, 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl₂ in 100 μ l,

and following a hot start 1U Taq polymerase was added. An initial denaturation cycle at 96°C/6 mins, 64°C/2 mins, 72°C/1 min and 30 seconds was followed by 30 cycles 94°C/1 min 30 seconds, 64°C/1 min 30 seconds, 72°C/1 min 30 seconds. The resultant 719 base pairs
5 fragment was cloned into pHe using the *Bgl* II and *Nco* I sites to give a chimeric *Cel-4* cassette which was subcloned, using the *Bam*HI sites, into the mammalian expression vector pSV VNP (Helm et al., supra (1991)). The orientation of this cassette was checked by PCR.

10 The identity of all gene constructs was confirmed by sequencing the DNA of both strands.

Example 2. Gene expression and purification of peptides

E. coli strains transformed with the expression plasmids were grown overnight at 37°C and the overnight culture was diluted 100 fold into LB broth containing 100µg/ml ampicillin and grown to an
15 absorbance of 0.4 at 600 nm at 37°C. The inducer IPTG (Sigma) was added to a final concentration of 0.1 mM and the cultures were grown under constant shaking at 37°C for 4h. Bacterial cells were harvested by centrifugation at 5,000g for 15 min and the pellets were frozen at -70°C until purification of the recombinant proteins.
20 Freezing and subsequent thawing of the bacterial pellets were essential to obtain effective solubilization of the recombinant proteins which are expressed as insoluble inclusion bodies.

The chimeric PSV VNP construct was linearized using *Pvu* I and electroporated into the J558L plasmacytoma cell line. See Helm et
25 al., supra (1991). J558L cells were cultured in DMEM (10% FCS, Pen/Strep, Gentamicin) and selection medium (DMEM 10%FCS, Pen/Strep, Gentamicin, Mycophenolic acid, Xanthine and Hypoxanthine) was added 48 hours after electroporation. See Helm, et al., supra (1991). High secreting clones were selected by ELISA.

30 **Purification of recombinant GST- ϵ -chain fusion proteins from *E. coli* cell pellets** - This was carried out using procedures described for the purification of recombinant ϵ -chain fragments expressed in *E. coli* (Helm et al., supra (1988)). Frozen cell pellets were defrosted on ice before homogenization (5 fold pellet volume) in 0.05 M Tris-
35 HCl buffer pH 7.9 containing 2 mM EDTA, 0.1 mM dithiothreitol, 1 mM

5 β -mercaptoethanol, 0.25 M NaCl, 0.1% sodium deoxycholate, 25 μ g/ml PMSF, 5% glycerol. The homogenate were dispersed by sonication before addition of 100 μ g/ml lysozyme and 20 μ g/ml DNAase I. Homogenate were kept on a rotary shaker for 12-15h at 4°C before centrifugation at 10,000g for 10 min. The pellets were washed twice in 20 fold pellet volume of 0.05 M Tris-HCl buffer pH 7.9 containing 1 mM EDTA, 0.1 M NaCl, 25 μ g/ml PMSF. Inclusion bodies from cell pellets were solubilized in 0.05 M Tris-HCl buffer pH 7.9 containing 8 M urea, 1 mM EDTA, 0.1 M NaCl, 25 μ g/ml PMSF and dialyzed for 12h against 200 fold volume of the same buffer omitting urea, but with the addition of 0.1 mM dithiothreitol and 1 mM P-mercaptoethanol. Insoluble materials were removed by centrifugation and 30-75% of recombinant F-chain peptides were found in the supernatant fraction. Affinity purification from this fraction was carried out using a rabbit anti-GST antiserum coupled to Sepharose 4B. The chimeric h/r antibody was purified from cell culture supernatants using NP-specific affinity columns and analyzed by polyacrylamide gel electrophoresis (PAGE) and immunoblotting. See Helm, et al., *supra* (1988); Helm et al., *supra* (1991).

20 *Gel electrophoresis and immunoblotting* - PAGE and electroblotting procedures have been described before (Helm, et al., *supra* (1988); Helm et al., *supra* (1991). Blots were developed with a polyclonal horseradish peroxidase conjugated anti-hIgE antibody (Dako).

25 **Example 3. Ligand binding studies and cell culture**

hIgE VNP (Helm et al., *supra* (1991)) was iodinated as previously described and the conditions for ligand binding and cell culture have been published (Wilson et al., *supra*). Affinity purified GST-e-chain fusion peptides were iodinated at 0-4°C in 0.4 M phosphate pH 7.4/7.5 using 4.4 μ Ci of Na¹²⁵I and 150-300 μ g of peptide in tubes coated with 40 pg IODO GEN (Pierce). Following a 15 min incubation period, the reactions were terminated by removing fluid from the coated tubes. Each preparation was fractionated on a 140 ml Sephacryl S-200 column (Pharmacia), preequilibrated with binding

buffer (PBS/0.2% BSA pH 7.4), which effects the separation of dimers and monomers. Following γ -counting of collected fractions, peak fractions were pooled, aliquoted and stored at -70°C . Specific activity ranged from 5.8 - 15.5 $\mu\text{Ci}/\mu\text{g}$.

5 The conditions for maintenance of RBL-2H3 cell-lines transfected with the α -chain of hFc ϵ R1 (RBL-2/2/C) have been described. See Wilson et al., *supra*. RBL2/2/C clones were plated into 48 well plates at an initial plating density of 105 cells/well and incubated with 10 -6 M dexamethasone for 24h at 37°C . In
10 preliminary experiments, RBL-2/2/C cells were incubated with increasing concentrations of ^{125}I labelled ligands (0.1-7.5 pg/ml) to determine the minimum saturation concentrations for Fc ϵ -R1 binding. The proportion of molecules capable of binding to Fc ϵ R1 was 78-91% for ^{125}I -labelled h and h/r IgE VNP, while the bindable portion of the
15 ^{125}I -labelled GST- ϵ 226-547, GST- ϵ 326-547, GST- ϵ 340-547, and GST- ϵ -226-354 was 41%, 56%, 53%, and 27% respectively. The number of rFc ϵ molecules bound per cell was calculated on the basis that GST- ϵ 326-547 and GST- ϵ 340547 are dimers, while GST- ϵ -226-354 is a monomer.

Non-specific binding was determined using a 50-100 fold molar
20 excess of non-labelled hIgE, and the same amount of GST was used as a negative control. The binding of recombinant proteins to Fc ϵ R1 α was determined indirectly, after correcting for non-specific binding (7-17%), by calculating the percentage inhibition of ^{125}I -IgE bound to cells. To measure the inhibition (IC_{50}) of ^{125}I -IgE binding to RBL-2/2/C
25 or the 8866 lymphoblastoid cell line (Helm et al., *supra* (1993) by native and chimeric h/rIgE VNP, and recombinant ϵ -chain fragments, cells were pre-incubated with a 25, 50, 100, and 200 fold molar excess of each of the unlabelled peptides in $^{125}\mu\text{l}$ binding buffer or, as control, binding buffer alone at 22°C for 1h, before the addition
30 of $50\mu\text{l}$ binding buffer containing $2\mu\text{g}/\text{ml}$ ^{125}I -IgE. After 45 min, the cells were washed twice with 0.5 ml ice cold binding buffer and lysed with 0.5 ml lysis buffer (0.5 M NaOH/1% Triton X-100). Samples (0-25 ml) were removed and counted for 5 min on a LKB1277 γ -counter.

The kinetics of association between RBL-2/2/C cells and ^{125}I -
35 labelled h and h/r chimera, GST- ϵ 226-547, GST- ϵ -326-547, GST- ϵ -340-547 ($2\mu\text{g}/\text{ml}$, in binding buffer) and GST- ϵ 226-354, ($0.7\mu\text{g}/\text{ml}$, in

binding buffer) were measured at 22°C during the first 300 seconds of incubation at pH 7.4. Rate constants were calculated on the basis that GST-F-226-547, GST-e326-547 and GST-e-340-547 are dimers, while GST-e226-354 is a monomer. The forward rate constant (K^+) was
5 calculated as $VO/CO \times RO$, where VO represents the initial rate of binding, and CO and RO represent the concentration of ligand and receptor number (-130,000 h α -chains per cell. See Wilson et al.,
supra. To determine the dissociation rate constant (K^-), cells were pre-incubated for 1h at 22°C with 125 μ l of the 125I-labelled h, and r
10 IgE, the h/r chimera, GST-e-226-547, GST-e326-547, GST-e340-547 and GST-e226-354/7 (ligand concentration as for the determination of K^+). Cells were washed twice with 0.5 ml binding buffer before 125 μ l binding buffer containing a 50 fold molar excess of unlabelled hIgE or binding buffer was added. At TO and after 15, 30, 60, 120, and
15 180 min intervals, the cells were washed twice with 0.5 ml ice cold binding buffer, solubilized in 0.5 ml lysis buffer (0.5 M NaOH/1% Triton X-100), and 0.25 ml samples were assayed for cell bound 125I.

The pH optimum for the binding of 125I-labelled hIgE and the GST-e-chain fragments to Fc ϵ R1 was determined by incubating RBL-2/2/C
20 cells (Wilson et al., supra) in 48 well plates 50 mM phosphate buffered saline containing 0.2% BSA (pH range 5.9-8.1) for 10 min at 37° C before adding 50 μ l of 2 μ g/ml 125I-h or rIgE or 0.7 μ g/ml of the 125I-GST-e fragments. Cells were incubated for 30 min and the excess-protein was removed by washing with saline containing 0.2% BSA before
25 measurement of cell bound label. Results were corrected for nonspecific binding.

Potassium iodide titration - The generation of IgE mutant VNpHeCys 328 -> Met has been described. See Helm et al., supra (1991). The conformations of native and mutant (Cys 328 -> Met)
30 recombinant IgE were investigated by comparing their intrinsic fluorescence. Solute quenching of protein fluorescence involved excitation of Trp residues at 297 nm and measurement of emission in the range 300-450 nm. Potassium iodide was added gradually to give a quench profile for each protein. Mathematical analysis was carried
35 out according to the Stern-Volmer Law. See Lehrer, *Methods Enzymol.* 49: 222-226 (1978).

Example 4. Identification of core sequence

The present study focused on the identification of the site(s) that determine the interaction of hIgE with its cellular receptors. The strategies employed for the expression of an overlapping family of chimeric GST-he-chain fusion proteins are outlined in Figure 1. Panels 1A & 1B summarize the receptor binding capacities of the GST-he-chain fusion proteins, that of a chimeric C/7 peptide, and a chimeric h/r IgE molecule. The assignment of biological activities is based on inhibition and direct binding studies detailed in Table 1. In Figure 1, panels C & D show the electrophoretic mobilities of C- and N-terminally truncated recombinant GST-he-chain fusion proteins immunoprecipitated with a rabbit anti-GST anti-serum, followed by PAGE analysis under non-reducing conditions, and immunoblotting with a horseradish peroxidase labelled rabbit anti-IgE serum. As shown in Figure 1C, C-terminal truncation yields a number of F--chain peptides for each construct. As judged by PAGE (Figure 1, panel C) and column chromatography (data not shown), approximately one third of the peptides in each set corresponds to the full length fusion peptide as a monomeric fragment. None of these fragments show any propensity to dimerize, although biologically inactive polymeric aggregates form at concentrations >1.3 mg/ml. A set of identical fragments is observed following analysis under reducing conditions (data not shown). Most of the smaller e-chain fragments represent proteolytic cleavage fragments which are recognized by monoclonal antibodies specific for the Ce2 domain (data not shown). In contrast, deletion of N-terminal sequences gives rise to two e-chain fragments and their apparent molecular weight under nonreducing (Figure 1, panel D) and reducing conditions (data not shown) indicates that they correspond, in almost equal quantities, to monomeric and dimeric GST-he-chain fusion proteins.

The data show that only those polypeptides that contain Ce4 or the homologous Cy3 domain can engage both FceR1 and FceR2 while C-terminal truncation of the e-chain results in elimination of binding to Fce-R2. See Helm et al., supra (1988); Vercelli et al., supra. As shown in Figure 1 panel 1A, sequences common to all fragments

capable of binding to hFcεR1α comprise residues Pro343-Ser353 in the Ce3 domain. Further deletion from either the C- or N-terminal end beyond these residues is associated with a loss of FcεR1 binding.

As shown in Figure 2 and Table I, GST·ε-(340-547) and GST·ε-(226-354), which comprise the core peptide, inhibit the binding of hIgE with an IC₅₀ in the nanomolar range. In contrast, blocking of IgE/FcεRI interaction by the GST controls GST·ε-(226-340), GST·ε-(355-547), and GST·ε-(355-547) cannot be detected even above micromolar concentrations.

As shown in the model structure of hIgE-Fc of Figure 3, this sequence forms a loop that is homologous to the loop in rIgG shown to bind to the neonatal FcγRn. See Burmeister et al., *Nature* 372: 379-384 (1994). A further similarity emerged when we investigated the pH dependency of the binding of hIgE to FcεR1. As shown in Figure 3 two pH optima are observed for the binding of hIgE to FcεR1, and occupancy of the receptor is almost twice as high at pH 6.4 than at 7.4. Although the significance of this is not known, it is tempting to speculate that IgE has evolved the lower pH optimum as a result of its physiological importance in the fight against parasitic infestations in the lumen of the intestine at acid pH.

Data summarized in Table 1 show that N- or C-terminal truncation has a negligible effect on the rate of association of biologically active ε-chain fragments with FcεR1. In contrast, the rate of dissociation increases several hundred fold following the deletion of residues from the C-terminal end and, as shown in Figure 3, this is associated with a concomitant decrease in receptor occupancy at pH 6.4. Taken together, these data suggest that His residues in the C-terminal region of the IgE molecule make a contribution towards the maintenance of the high affinity interaction between IgE and FcεR1α since this is largely determined by the slow rate of dissociation of the ligand from the receptor.

The data show that the essential determinant for hIgE/FcεR1 recognition depends on a consecutive sequence comprising eleven amino acids computed to form a loop at the interface between the Ce-3 and Ce-4 domain. These observations exclude any direct contribution of Ce4-specific residues as proposed by Stanworth et al. See Stanworth

et al., *supra.*; Weetall et al., *J. Immunol.* **145**: 3849-54 (1990); and Nissim et al., *supra* (1991, 1992, and 1993). These results confirm and extend those made by Nissim et al., who demonstrated that the receptor binding site in IgE is located in the Ce3 domain, and differ
5 from the conclusions of Hamburger and Gould et al. Thus, Gould et al., propose that residues 330-334 and 329-340 in the switch region between Ce2 and Ce3 are essential for IgE/FcεRI binding. See Hamburger, *Science* **189**: 389-391 (1975) and Gould et al., *Biochem. Soc. Trans.* **21**: 968-972 (1993); *Nature* **366**, 421-428 (1993). As the
10 results of our study clearly demonstrate, these sequences can be deleted without any major influence on the kinetics of hIgE/FcεRI interaction.

It is interesting to note that the active core sequence identified by us overlaps the hIgE-derived peptide generated by Nio
15 et al., who report its capability to block the binding of antigen-specific IgE to cells expressing FcεRI at concentrations in the mM range. See Nio et al., *Peptide Chemistry* **2**, 203-206 (1989).

The results of our study indicate that fragments containing the Ce-2 domain are susceptible to proteolysis (Figure 1, panel C). The
20 inclusion of the protease inhibitor phenyl methyl sulfonyl fluoride (PMSF) during the isolation procedure facilitates the purification of polypeptides that engage FcεR1 and FcεR2.

Sequences N- or C-terminal to this core peptide are necessary to provide structural scaffolding for the maintenance of a receptor
25 binding conformation since the core peptide alone cannot engage the receptor. Deletion of C-terminal, but not N-terminal sequences diminishes receptor occupancy at pH 6.4 and increases the dissociation of the ligand from the receptor, and we conclude that residues, including His, in the C-terminal domain make an important
30 contribution towards the maintenance of the high-affinity of interaction between IgE and FcεR1α. Thus, the sequence herein identified as a core sequence overlaps but is different from those previously identified by others.

TABLE I

*Binding of native and recombinant human and rat
IgE-derived ϵ -chain fragments to hFc ϵ RI α*

The kinetics of association and dissociation of the affinity-
5 purified ligands were determined at 22°C. Kinetic constants and
IC₅₀, which represents the concentration at which 50% inhibition of
125I-IgE V_{NP}h ϵ binding was obtained, were calculated on the basis that
GST · ϵ -(226-547), GST · ϵ -(326-354), and GST · ϵ -(340-547) form
dimers, while GST · ϵ -(226-354) is a monomer. Nonbinding ligands
10 used at 10⁻⁵ M showed no binding above background. Data shown
represent the calculated mean of experiments carried out in
duplicate.

Ligand	k_{+1} M ⁻¹ s ⁻¹	k_{-1} s ⁻¹	K_d M	IC ₅₀ nM	n
hIgE	3.14 x 10 ⁵	1.3 x 10 ⁻⁵	4.1 x 10 ⁻¹¹	14	>8
15 hIgE r ϵ -(341-356)	4.3 x 10 ⁴	1.7 x 10 ⁻⁵	3.9 x 10 ⁻¹⁰	ND ^a	1
GST ϵ -(226-547)	3.6 x 10 ⁵	1.6 x 10 ⁻⁵	4.4 x 10 ⁻¹¹	18	2
GST ϵ -(326-547)	4.1 x 10 ⁵	2.95 x 10 ⁻⁵	7.2 x 10 ⁻¹¹	23	2
GST ϵ -(340-547)	4.2 x 10 ⁵	9.8 x 10 ⁻⁵	2.3 x 10 ⁻¹⁰	34	2
20 GST ϵ -(226-354)	4.3 x 10 ⁵	6.02 x 10 ⁻³	1.4 x 10 ⁻⁸	332	3

^a not determined

Example 5. Anti-oligopeptide polyclonal serum production

Anti-sera from rabbits were obtained by immunization with both
constrained and unconstrained oligopeptide. The oligopeptide
employed was C L S R P S P F D L F I R K S P T I T S C C. The
25 constrained form was obtained by incubation of 0.5 mg/ml of
oligopeptide dissolved in 50 mM ammonium bicarbonate for two hours
with stirring at room temperature, and then for 90 hrs. at 4°C. The
formation of the constraining disulfide bond and the formation of the
oligopeptide loop were followed by mass spectrometry; loop formation
30 occurred after three days of standing. After 90 hrs. the sample was
lyophilized. Two rabbits each were used. Rabbits were immunized by
subcutaneous injection with 100 micrograms each of oligopeptide
suspended in PBS/FCA (PBS = phosphate buffered saline, FCA = Freund's
complete adjuvant) (v/v). At two-week intervals, the rabbits

received another dose of immunogen in the same concentration but this time suspended in PBS/FIA (FIA = Freund's incomplete adjuvant) (v/v). After the third and last injection (in PBS/FIA), the serum was screened by ELISA for the presence of polyclonal antibodies against the oligopeptide immunogen. Four days after a final intravenous injection (boost), the blood was collected and left at room temperature until clotted. The serum was collected with a Pasteur pipette followed by centrifugation at 3,000 rpm for 10 min in order to separate remaining erythrocytes. Serum aliquots of 1 ml were transferred to Eppendorf tubes and frozen at -20° C until further use. The titer for the constrained oligopeptide used in ELISA was 1:1000; that for the unconstrained oligopeptide it was 1:100.

Example 6. Inhibition of IgE binding to receptor

Three different parameters were investigated.

(1) RBL-2/2C cells were incubated overnight with 5-hydroxytryptamine (5-HT) and with JW8 IgE (Serotec USA, Wash. D.C.) for 24 hours. See Wilson et al., supra (1993a, 1993b). The cells were washed 2 times and challenged with the anti-sera raised against the oligopeptides diluted 1:50, 1:100, 1:250, 1:500, and 1:1000. After 15 min, 5-HT release was determined. No 5-HT release was observed under these conditions. In control experiments, cells were incubated overnight in the same fashion, but challenged on day 2 with either JW8 IgE-specific antigen, i.e. 5-iodo,4hydroxy,3-nitrophenyl linked to human serum albumin (NIP-HSA) or a monoclonal antibody directed against the Ce2 or Ce4 domain, approximately 30% of total cellular 5-HT content was released. This shows that the anti-constrained oligopeptide antiserum does not trigger release of 5-HT by cells sensitized with IgE.

(2) RBL-2/2/C cells were incubated with 5-HT for 24 hrs. after which the cells were washed 2 times as above. 0.5 ug/ml of JW8 IgE was incubated overnight with anti-constrained and unconstrained oligopeptide serum (diluted in buffer 1:5, 1:10, 1:50, 1:100, 1:250). 5-HT release was measured after a 15-min incubation period. No 5-HT release was observed. In control experiments where IgE was incubated overnight in the same fashion with monoclonal antibodies directed

against epitopes on either the Ce2 or Ce4 domain, approximately 30% of total cellular 5-HT content was released when these were added to the cells.

- 5 (3) RBL-2/2/C cells were incubated with 5-HT for 24 hours after which the cells were washed 2 times as before. 0.5 ug/ml of JW8 IgE was incubated overnight with anti-serum against the constrained and unconstrained oligopeptides (diluted in buffer 1:5, 1:10, 1:50, 1:100, 1:250). The IgE and anti-serum were added to the washed cells and these were incubated for 1 hour in a tissue culture incubator.
- 10 For conditions, see Wilson et al., supra (1993). Cells were washed 2 times with buffer, NIP-HSA was added (10 ng/ml), and 5-HT release measured after 15-min of incubation. No 5-HT release was observed when cells were incubated with the anti-serum against the constrained oligopeptide at dilutions between 1:10 to 1:100. In control
- 15 experiments, cells sensitized with 0.5 ug/ml NIP-specific JW8 IgE, followed by challenge with NIP-HSA, released approximately 30% 5-HT. Cells that were incubated with the anti-serum against the unconstrained oligopeptide, where this was diluted 1:10, showed a nearly 30% release of 5-HT.
- 20 The formation of the disulfide-constrained oligopeptide was monitored using a V9 platform (Fisons) Electron Spin Resonance spectroscopy with positive electrospray vaporization, where the mobile phase had 50% acetonitrile, 50% water plus 1% formic acid added to the sample mix with approximately 1 ug of oligopeptide.
- 25 Disulfide bond formation occurred after 3 days standing.

Although the foregoing refers to particular preferred embodiments, it will be understood that the present invention is not so limited. It will occur to those of ordinary skill in the art that

30 various modifications may be made to the disclosed embodiments and that such modifications are intended to be within the scope of the present invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- 5 (i) APPLICANT: Padlan et al.
- (ii) TITLE OF INVENTION: Inhibition of IgE-Mediated
Allergies By A Human IgE-Derived
Oligopeptide
- (iii) NUMBER OF SEQUENCES: 9
- (iv) CORRESPONDENCE:
- 10 (A) ADDRESSEE: Klarquist Sparkman Campbell Leigh &
Whinston, LLP
- (B) STREET: One World Trade Center
121 S.W. Salmon Street
Suite 1600
- (C) CITY: Portland
- 15 (D) STATE: Oregon
- (E) COUNTRY: U.S.A.
- (F) ZIP: 97204-2988
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: 3.5" Disk
- 20 (B) COMPUTER: IBM-PC compatible
- (C) OPERATING SYSTEM: Windows NT
- (D) SOFTWARE: WordPerfect 7.0/ASCII
- (vi) CURRENT APPLICATION DATA: Filed herewith
- (A) APPLICATION NUMBER:
- 25 (B) FILING DATE:
- (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: U.S. Provisional 60/031,991
- (B) FILING DATE: December 12, 1996
- 30 (viii) ATTORNEY/AGENT INFORMATION
- (A) NAME: David J. Earp, Ph.D.
- (B) REGISTRATION NUMBER: 41,401
- (C) REFERENCE/DOCKET NUMBER: 4239-48989
- (ix) TELECOMMUNICATION INFORMATION:
- 35 (A) TELEPHONE: (503) 226-7391

(B) TELEFAX: (503) 228-9446

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11

5 (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:1:

10 Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser

5 10

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22

15 (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:2:

Cys Leu Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser

5 10 15

20 Pro Thr Ile Thr Ser Cys Cys

20

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

25 (B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:3:

Cys Ser Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro

30 5 10 15

Thr Ile Thr Cys Cys

20

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: amino acid

5 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:4:

Cys Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr

5 10 15

10 Ser Cys Cys

18

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 16

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:5:

20 Cys Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Cys

5 10 15

Cys

16

(2) INFORMATION FOR SEQ ID NO:6:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

30 (ix) SEQUENCE DESCRIPTION: SEQ ID NO.:6:

CGTGAAGATC TTACAGTCGT C 21

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
5 (D) TOPOLOGY: linear
(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:7:
CCTGCCCATG GCTCACCG 18

(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
10 (A) LENGTH: 55
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:8:
15 CCTCGACCTG TATGAAAATG GGACTCCCAA ACTTACCTGT CTGGTGGTGG ACCTG 55

(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 56
(B) TYPE: nucleic acid
20 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ix) SEQUENCE DESCRIPTION: SEQ ID NO.:9:
CCATTTTCAT ACAGGTCGAG GGGACTGGGT GGGATTAGGT AGGCGCTCAC CCCTCT 56

What Is Claimed Is:

1. A purified oligopeptide that interacts with the Fce receptor, wherein the oligopeptide comprises the amino acid sequence:

P S P F D L F I R K S.

2. The purified oligopeptide according to claim 1 wherein the oligopeptide is fewer than 50 amino acids in length.

3. The purified oligopeptide according to claim 2 wherein the oligopeptide is 13-27 amino acids in length.

4. The purified oligopeptide according to claim 1, wherein said oligopeptide has been constrained to form a loop structure.

5. A purified oligopeptide comprising an amino acid sequence selected from the group consisting of the sequences set forth in Seq. I.D. Nos. 1-5.

6. A pharmaceutical preparation comprising a purified oligopeptide according to claims 1, 2, 3, 4 or 5.

7. An isolated DNA molecule encoding an oligopeptide according to claims 1, 2, 3, 4 or 5.

8. A biological system that expresses the DNA molecule of claim 7.

9. A biological system according to claim 8, wherein said biological system is a prokaryotic or a eukaryotic cell.

10. A method of preparing an oligopeptide competitor of IgE, comprising:

(a) culturing a prokaryotic or eukaryotic cell according to claim 9, and

(b) purifying said oligopeptide.

11. A competitive binding assay for hIgE wherein the competitor is an oligopeptide according to claims 1, 2, 3, 4 or 5.

12. An antibody raised against a purified oligopeptide according to claims 1, 2, 3, 4 or 5.

13. A pharmaceutical preparation comprising an antibody according to claim 12.

14. A diagnostic method for determining IgE levels in a sample of fluids comprising the steps of:

(a) contacting said sample with an antibody raised against an oligopeptide competitor to IgE; and

(b) precipitating IgE with said antibody.

15. The method of claim 14 wherein the antibody is an antibody raised against a purified oligopeptide according to claims 1, 2, 3, 4, or 5.

16. A diagnostic method of determining available Fcε receptors on the membrane of cells, comprising the steps:

(a) providing a sample of said cells;

(b) providing a labeled oligopeptide competitor to IgE; and

(c) determining the amount of label bound by said cells.

17. A kit for a diagnostic method for determining IgE levels, comprising an antibody of claim 12 and a container for said antibody.

18. A diagnostic kit for determining available Fcε receptors comprising a purified oligopeptide according to claims 1, 2, 3, 4 or 5, and a container for said polypeptide.

19. A method of targeting a cell which expresses FcεR1 receptor, comprising delivering into an organism an oligopeptide according to claim 1.

20. A protein that interacts with the FcεR1 receptor, wherein the protein consists essentially of the amino acid sequence P S P F D L F I R K S.

21. A protein that competes with IgE for the FcεR1 receptor, wherein the protein consists essentially of the amino acid sequence selected from the group consisting of the sequences set forth in Seq. I.D. Nos. 1-5.

22. A protein that competes with IgE for the FcεR1 receptor, wherein the protein consists essentially of:

- (i) an amino acid sequence P S P F D L F I R K S; and
- (ii) constraining residues that flank the amino acid sequence of (i), wherein the constraining residues include cysteine and are within 16 residues N-terminal and 4 residues C-terminal of the amino acid sequence of (i).

1/5


The FcεRI Binding Region in Human IgE

FIG. 1A

FcεRI			FcεRI	FcεRII interaction
Cε2	Cε3	Cε4		
FcεR2				
GST			-	-
GST-226		547	+	+
GST-226	161		+	-
GST-226	337		+	-
GST-226	334		+	-
GST-226	333		+	-
GST-226	332		-	-
GST-226	340		-	-
GST-340	337		-	-
	GST-440	547	-	-
	GST-330	547	-	-
	GST-343	547	-	-
	GST-344	547	-	n.d.
	GST-343	547	+	n.d.
	GST-342	547	+	n.d.
	GST-340	547	+	+
	GST-330	547	+	+
	GST-326	547	+	+
GST-226		Cγ3	+	+

FIG. 1B

		hFcεRI	rFcεRI	hFcεRII
		interaction		
IgE VNP he	M 328	+	-	n.d.
IgE VNP he	h → r rs341-356	+	-	-

2/5




FIG. 1C




FIG. 1D

3/5




FIG. 2

4/5




FIG. 3

5/5




FIG. 4

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/22348

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K7/06 C07K7/08 C07K16/42 A61K39/395 G01N33/68
G01N33/563

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	B.A. HELM ET AL: "Identification of the high affinity receptor binding region in human immunoglobulin E" JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 271, no. 13, 29 March 1996, MD US, pages 7494-7500, XP002067058	1-11, 20-22
Y	see the whole document see page 7495, paragraph 1 --- -/--	16,18,19

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

4 June 1998

Date of mailing of the international search report

24.06.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

INTERNATIONAL SEARCH REPORT

Inte. Application No
PCT/US 97/22348

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GHADERI ET AL: "Epitope mapping of the sites of binding of Fc epsilon within human IgE" MOLECULAR IMMUNOLOGY, vol. 30, no. 18, 1993, pages 1655-1663, XP002067059	11-15, 17,20-22
Y	see the whole document *peptide F39, Table 1* see page 1657, column 1, last paragraph see page 1657, column 2, paragraph 2	16,18,19
X	WO 95 20606 A (PASTEUR MERIEUX SERUMS VACC ;HURPIN CHRISTIAN MARCEL (FR); LATOUR) 3 August 1995	1,5-13
Y	see page 5, paragraph 1 see page 7, paragraph 2 see claims 1,3,24,26,29	16,18,19
X	WANG Y: "PEPTIDES DERIVED FROM IG HEAVY CHAIN CONSTANT REGION INDUCE PROFOUND IGE ISOTYPE-SPECIFIC TOLERANCE" EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 26, no. 5, May 1996, pages 1043-1049, XP000645198 see the whole document *Peptide E*	1,6-11
X	WO 89 04834 A (RESEARCH CORP) 1 June 1989 see the whole document	1,6-11
X	NIO N ET AL: "INHIBITION OF ALLERGIC RESPONSES BY SYNTHETIC IMMUNOGLOBULIN E PEPTIDE FRAGMENTS AND THE DELINEATION OF THE BINDING SITES IN THE IMMUNOGLOBULIN E MOLECULE TO THE FC RECEPTOR" PEPTIDE CHEMISTRY, PROCEEDINGS 29TH SYMPOSIUM ON PEPTIDE CHEMISTRY, TOKYO, OCT. 24-26, 1991, 1987, pages 765-768, XP000654192 *see table 1 - peptide N. 2* see the whole document	1-6
Y	WO 95 25957 A (MERCK & CO INC ;KONTEATIS ZENON (US); SICILIANO SALVATORE J (US);) 28 September 1995 see claim 1	16,18
Y	WO 87 02061 A (BIOTECH RES PARTNERS LTD) 9 April 1987 see claim 1	19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/22348

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 19 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/22348

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9520606 A	03-08-1995	FR 2715304 A AU 1538895 A	28-07-1995 15-08-1995
WO 8904834 A	01-06-1989	AT 108458 T AU 2802289 A DE 3850654 D DE 3850654 T DK 354489 A EP 0341290 A JP 2502191 T JP 2721256 B US 5693758 A	15-07-1994 14-06-1989 18-08-1994 15-12-1994 19-09-1989 15-11-1989 19-07-1990 04-03-1998 02-12-1997
WO 9525957 A	28-09-1995	US 5614370 A	25-03-1997
WO 8702061 A	09-04-1987	AU 6408586 A EP 0238645 A	24-04-1987 30-09-1987



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 7/06, 7/08, 16/42, A61K 39/395, G01N 33/563, 33/68	A3	(11) International Publication Number: WO 98/24808 (43) International Publication Date: 11 June 1998 (11.06.98)
(21) International Application Number: PCT/US97/22348 (22) International Filing Date: 5 December 1997 (05.12.97) (30) Priority Data: 60/031,991 6 December 1996 (06.12.96) US (71) Applicant (for all designated States except US): THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH [US/US]; Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): PADLAN, Eduardo, A. [US/US]; 4006 Simms Drive, Kensington, MD 20895 (US). BIRGIT, A., Helm [DE/GB]; 3 Hopton House, 27, Collegiate Crescent, Sheffield S10 2BJ (GB). (74) Agent: EARP, David, J.; Klarquist, Sparkman, Campbell, Leigh & Whinston, LLP, Suite 1600, One World Trade Center, 121 S.W. Salmon Street, Portland, OR 97204 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i> (88) Date of publication of the international search report: 13 August 1998 (13.08.98) Date of publication of the amended claims: 12 November 1998 (12.11.98)
(54) Title: INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE (57) Abstract <p>Peptides are disclosed that are capable of effective recognition of the human IgE Fcε receptor. The peptides partially comprises a fragment of human IgE. By addition of constraining amino acid residues at or near the polypeptides' N- and C-termini, these peptides may be forced to assume a loop configuration. These constrained peptides are useful as competitors of human IgE for the Fcε receptor, and may be used to block the development of type I hypersensitivity.</p>		

*(Referred to in PCT Gazette No. 40/1998, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

AMENDED CLAIMS

[received by the International Bureau on 24 August 1998 (24.08.98);
original claims 1-22 replaced by amended claims 1-25 (3 pages)]

1. A purified oligopeptide that interacts with the Fcε receptor, wherein the oligopeptide consists essentially of the amino acid sequence:
P S P F D L F I R K S.
2. The purified oligopeptide according to claim 1 wherein the oligopeptide is fewer than 50 amino acids in length.
3. The purified oligopeptide according to claim 2 wherein the oligopeptide is 13-27 amino acids in length.
4. The purified oligopeptide according to claim 1, wherein said oligopeptide has been constrained to form a loop structure.
5. A purified oligopeptide that interacts with the human Fcε receptor and consists essentially of an amino acid sequence selected from the group consisting of the sequences set forth in Seq. I.D. Nos. 1-5.
6. A purified recombinant oligopeptide that interacts with the human Fcε receptor and has a structure A-X-B, wherein:
 - (a) X is an amino acid sequence consisting essentially of the sequence PSPFDLFIRKS or the sequence LSRPSPFDLFIRKSPTIT; and
 - (b) A and B are peptides that interact to constrain the oligopeptide into a loop structure.
7. The oligopeptide of claim 6 wherein the peptides A and B each contain at least one cysteine residue, and wherein the cysteine residues of the A and B peptides form disulfide bonds.
8. A pharmaceutical preparation comprising a purified oligopeptide according to claims 1-7
9. An isolated nucleic acid molecule encoding an oligopeptide according to claims 1-7.
10. A biological system that expresses the nucleic acid molecule of claim 9.
11. A biological system according to claim 10, wherein said biological system is a prokaryotic or a eukaryotic cell.
12. A method of preparing an oligopeptide competitor of IgE, comprising:

- (a) culturing a prokaryotic or eukaryotic cell according to claim 11, and
- (b) purifying said oligopeptide.

13. A competitive binding assay for hIgE wherein the competitor is an oligopeptide according to claims 1-7.

14. An antibody raised against a purified oligopeptide according to claims 1-7.

15. A pharmaceutical preparation comprising an antibody according to claim 14.

16. A diagnostic method for determining IgE levels in a sample of fluids comprising the steps of:

- (a) contacting said sample with an antibody raised against an oligopeptide competitor to IgE; and
- (b) precipitating IgE with said antibody.

17. The method of claim 16 wherein the antibody is an antibody raised against a purified oligopeptide according to claims 1-7.

18. A diagnostic method of determining available Fcε receptors on the membrane of cells, comprising the steps:

- (a) providing a sample of said cells;
- (b) providing a labeled oligopeptide competitor to IgE, wherein the oligopeptide competitor is an oligopeptide according to claim 1-7; and
- (c) determining the amount of label bound by said cells.

19. A kit for a diagnostic method for determining IgE levels, comprising an antibody of claim 17 and a container for said antibody.

18. A diagnostic kit for determining available Fcε receptors comprising a purified oligopeptide according to claims 1-7, and a container for said polypeptide.

20. A method of targeting a cell which expresses FcεR1 receptor, comprising delivering into an organism an oligopeptide according to claims 1-7.

21. The method of claim 21 wherein the oligopeptide is conjugated with at least one other molecule that is to be delivered to the cell.

22. A protein that competes with IgE for the FcεR1 receptor, wherein the protein consists essentially of an amino acid sequence selected from the group consisting of the sequences set forth in Seq. I.D. Nos. 1-5.
23. An oligopeptide that interacts with the human Fcε receptor and has a structure A-X-B, wherein:
- (a) X is an amino acid sequence consisting essentially of the sequence PSPFDLFIRKS or the sequence LSRPSPFDLFIRKSPTIT; and
 - (b) A and B are constraining peptides that each include at least one cysteine residue, wherein the cysteine residues of the A and B peptides form disulfide bonds.
24. An oligopeptide according to claim 23 wherein the constraining peptides include a cysteine residue with 16 residues N terminal and 4 residues C terminal of X.
25. An oligopeptide according to claim 23 wherein the oligopeptide is no more than about 50 amino acids in length.

